Introduction {#Sec1}
============

Lymphoma is the most common lymphoid malignancy and is among the ten most prevalent cancers worldwide.^[@CR1]^ Lymphoma is a heterogeneous entity and includes Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). HL accounts for 10--15% of lymphoma and is characterized by the presence of Reed--Sternberg cells. NHL accounts for 80--85% of lymphoma, including B-cell NHLs (B-NHLs) expressing CD20 or CD19, T-cell NHLs (T-NHLs) expressing CD3, CD4, or CD8, and natural killer (NK)/T-cell NHLs expressing CD56. Chemotherapy is the standard of care for lymphoma patients. The introduction of monoclonal antibodies targeting surface antigens has greatly changed the therapeutic landscape of lymphoma. For example, rituximab, an anti-CD20 antibody targeting CD20 in B-NHLs and brentuximab vedotin targeting CD30 in classical HL and T-NHLs, have significantly improved the response rates and clinical outcomes of patients.^[@CR2],[@CR3]^ In addition, growing insights into molecular biology and signaling pathways have led to the development of many innovative agents for lymphoma in recent years.^[@CR4]^ More recently, with a better understanding of the crosstalk between malignant lymphocytes and the tumor microenvironment, chimeric antigen receptor T-cells (CAR-T cells) have been rapidly developed in treating relapse and refractory patients.^[@CR5],[@CR6]^ Although the overall survival (OS) of lymphoma patients has been considerably improved by the new immunochemotherapeutic regimens, the selection of targeted agents and the optimal dosage are important due to treatment-related adverse events (AEs). In this review, we systematically outlined the advances in targeted therapy for malignant lymphoma that provide significant improvement in mechanism-based lymphoma treatment in the era of precision medicine.

Surface antigens and targeted therapies {#Sec2}
=======================================

Surface antigens are the most accessible part of lymphoma cells, and monoclonal antibodies (mAbs) targeting surface antigens have become important therapeutic strategies in many lymphoid malignancies. Cytotoxic to tumor cells, mAbs relatively spare normal tissues. The mechanisms of action include the induction of apoptosis, antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). In addition to "bare" antibodies, antibodies or their fragments may be linked with cell toxins, immunotoxins, or radioisotopes to increase clinical efficacy.

CD20 {#Sec3}
----

The CD20 molecule is a transmembrane protein involved in B-cell activation and differentiation and is present on all mature B-cells and most B-NHL cells.^[@CR7]^ Moreover, without internalization or downregulation following antibody binding, CD20 functions as an ideal therapeutic target for most B-NHLs.^[@CR8]^ Moreover, pro-B cells and antibody-producing plasma cells do not express CD20, so anti-CD20 treatment will not impair the healthy B-cell population.

Anti-CD20 mAbs are classified as type I and type II.^[@CR9]^ Type I antibodies most effectively induce CDC, in which the binding of the mAb activates a complement cascade. Type I antibodies also induce ADCC, in which immune cells expressing Fc gamma receptor (FcγR) attack antibody-coated cells. Type II antibodies initiate ADCC as well as cell death through apoptotic or non-apoptotic mechanisms.

Rituximab was the first mAb to target CD20 and the first mAb approved to treat cancer patients. It is a chimeric antibody with a murine variable region and a human IgG1-kappa constant region,^[@CR8]^ classified as a type I mAb. The significant anti-lymphoma activity of rituximab in early trials^[@CR3],[@CR10]--[@CR12]^ has led to its widespread use in most CD20^+^ B-NHLs.

The targeted agents and clinical trials related to mAbs are listed in Table [1](#Tab1){ref-type="table"}. Ofatumumab is a fully humanized second-generation type I CD20 antibody that exhibits more potent CDC than rituximab in vitro.^[@CR13]^ Ofatumumab is approved in combination with chlorambucil for chronic lymphocytic leukemia (CLL).^[@CR14],[@CR15]^ Moreover, the results from a phase 2 trial (NCT00410163) suggested that ofatumumab in combination with fludarabine and cyclophosphamide was efficient in untreated CLL patients.^[@CR16]^ The main AEs were infusion-related reactions and grade 1--2 infections.Table 1Targeted agents and clinical trials related to monoclonal antibodiesDrugDiseaseTrial namePhaseStatusORR/CRNCT\#Reference*Anti-CD20 antibodyOfatumumabA fully humanized second-generation type I CD20 antibody*Ofatumumab, fludarabine, cyclophosphamideCLLOfatumumab with fludarabine and cyclophosphamide in b-cell chronic lymphocytic leukemia patients2Completed500 mg, 77%/42%; 100 mg, 73%/50%NCT00410163^[@CR16]^*ObinutuzumabA humanized type II CD20 antibody*ObinutuzumabRelapsed or refractory DLBCL/MCLA dose-escalating study of obinutuzumab in patients with b-lymphocyte antigen (CD20^+^) malignant disease (gauguin)1/2CompletedDLBCL, 28%/4%; MCL, 27%/13%NCT00517530^[@CR19]^Obinutuzumab, bendamustine vs. bendamustineRituximab-refractory iNHLsA study to investigate the efficacy and safety of bendamustine compared with bendamustine plus obinutuzumab in participants with rituximab-refractory, indolent non-Hodgkin's lymphoma (GADOLIN)3CompletedObinutuzumab plus bendamustine, 69%/11%; bendamustine monotherapy, 63%/12%NCT01059630^[@CR20]^Obinutuzumab, CHOP/CVP/bendamustine vs. rituximab, CHOP/CVP/bendamustineUntreated iNHLsA study of obinutuzumab (RO5072759) plus chemotherapy in comparison with rituximab plus chemotherapy followed by obinutuzumab or rituximab maintenance in patients with untreated advanced indolent non-Hodgkin's lymphoma (GALLIUM)3Active, not recruitingFL: obinutuzumab group, 88.5%/19.5%; rituximab group, 86.9%/23.8%NCT01332968^[@CR21]^Obinutuzumab, CHOP/FC/bendamustineFLA study of obinutuzumab in combination with chemotherapy in participants with CD20^+^ B-cell follicular non-Hodgkin's lymphoma1CompletedG-CHOP, 96%/39%; G-FC, 93%/50%NCT00825149^[@CR22]^G-Clb vs. Clb vs. R-ClbUntreated CLLCLL11: a study of obinutuzumab with chlorambucil in patients with previously untreated chronic lymphocytic leukemia (Stage 1a)3CompletedG-Clb, 77.3%/22.3%; Clb, 31.4%/0%; R-Clb, 65.7%/7.3%NCT01010061^[@CR23]^Obinutuzumab, ibrutinib vs. obinutuzumab, chlorambucilUntreated CLL/SLLA multicenter study of ibrutinib in combination with obinutuzumab versus chlorambucil in combination with obinutuzumab in patients with treatment naïve CLL or SLL3CompletedObinutuzumab plus ibrutinib, 91%/41%; obinutuzumab plus chlorambucil, 81%/16%NCT02264574^[@CR24]^*UblituximabA type I, chimeric, recombinant IgG1 monoclonal antibody targeting a unique epitope on the CD20 antigen, glycoengineered to enhance affinity for all FcRIIIa variants*Ublituximab, ibrutinibCLL/MCLUblituximab plus ibrutinib in select B-cell malignancies1/2Completed88%/5%NCT02013128^[@CR27]^Ublituximab, ibrutinib vs. ibrutinibPreviously treated high-risk CLLUblituximab in combination with ibrutinib versus ibrutinib alone in patients with previously treated high-risk chronic lymphocytic leukemia3Active, not recruitingcombination arm, 78%/7%; monotherapy, 45%/0%NCT02301156^[@CR28]^Ublituximab, umbralisib vs. obinutuzumab, chlorambucilCLLUblituximab plus umbralisib compared to obinutuzumab plus chlorambucil in patients with untreated and previously treated chronic lymphocytic leukemia3Active, not recruiting--NCT02612311--Ublituximab, umbralisib; ublituximab, umbralisib, ibrutinibB-NHLs, CLLUblituximab in combination with umbralisib +/− ibrutinib or bendamustine in patients with B-cell malignancies1CompletedUblituximab, umbralisib, ibrutinib, 84%/30%; ublituximab, umbralisib, 46%/17%NCT02006485^[@CR29],[@CR30]^*VeltuzumabA humanized type I anti-CD20 monoclonal antibody*VeltuzumabRelapsed or refractory B-NHLsStudy of humanized anti-CD20 in patients with CD20^+^ non-Hodgkin's lymphoma1/2CompletedFL, 44%/27%; MZL, 83%/33%; DLBCL, 43%/0%NCT00285428^[@CR31]^*OcrelizumabA humanized type I anti-CD20 monoclonal antibody*OcrelizumabRelapsed or refractory FLAn open-label, multicentre, dose-escalating phase 1/2 trial of 3-weekly ocrelizumab in patients with follicular non-Hodgkin's lymphoma1/2Completed38%/15%NCT02723071^[@CR32]^*CT-P10A rituximab biosimilar*CT-P10 vs. rituximabFLTo compare efficacy and safety between CT-P10 and rituxan in patients with low tumor burden follicular lymphoma3Active, not recruitingCT-P10, 83%/28%; rituximab, 81%/34%NCT02260804^[@CR33]^CT-P10, CVP vs. R-CVPFLTo demonstrate equivalence of pharmacokinetics and noninferiority of efficacy for CT-P10 in comparison with rituxan3CompletedCT-P10, CVP, 97%/30%; R-CVP, 93%/22%NCT02162771^[@CR34]^*GP2013A rituximab biosimilar*GP2013, CVP vs. R-CVPUntreated advanced-stage FLGP2013 in The treatment of patients with previously untreated, advanced-stage follicular lymphoma3CompletedGP2013, CVP, 87%/15%; R-CVP, 88%/13%NCT01419665^[@CR35]^*PF-05280586A rituximab biosimilar*PF-05280586 vs.rituximabFLA study of PF-05280586 (Rituximab-Pfizer) or MabThera® (Rituximab-EU) for the First-Line treatment of patients with CD20^+^, low tumor burden, follicular lymphoma (REFLECTIONS B328-06)3CompletedPF-05280586, 76%/26%; rituximab, 71%/28%NCT02213263^[@CR36]^*ABP798A rituximab biosimilar*ABP798 vs. rituximabB-NHLsStudy to assess if ABP798 Is safe and effective in treating non-Hodgkin's lymphoma compared to rituximab3completedNANCT02747043--^*90*^*Y-ibritumomab tiuxetanA radiolabeled anti-CD20 monoclonal antibody which targets the same epitope on the CD20 molecule like rituximab and chelates the radioactive particle Yttrium-90*^90^Y-ibritumomab tiuxetanFL^90^Y-Ibritumomab tiuxetan first line in follicular lymphoma2Unknown status87%/56%NCT00772655^[@CR41]90^Y-ibritumomab tiuxetanFLPhase 2 study of fractionated ^90^Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma2Completed95.8%/69.4%NCT01493479^[@CR42]90^Y-ibritumomab tiuxetan vs. no treatmentFLTreatment with ^90^Y-ibritumomab tiuxetan versus no treatment in patients with follicular non-Hodgkin's lymphoma (stage III or IV) having achieved a partial or complete pemission after first line chemotherapy3CompletedPR after induction therapy converted to a CR/CRu: consolidation arm, 77%; control arm, 17.5%NCT00185393^[@CR43],[@CR44]90^Y-ibritumomab tiuxetan, rituximab vs. rituximabUntreated FLRituximab with or without ^90^Y-Ibritumomab tiuxetan in treating patients with untreated follicular lymphoma3Recruiting--NCT02320292--^90^Y-ibritumomab tiuxetan vs. ASCTRelapsed or refractory FLA phase 3 multicenter, randomized study comparing ^90^Y-Ibritumomab tiuxetan vs. ASCT in patients with relapsed or refractory FL3Recruiting--NCT01827605--^90^Y-ibritumomab tiuxetan, BEAMFL/DLBCL/MCL/transformed lymphomasPhase 2 trial of a transplantation regimen of ^90^Y-Ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma2CompletedNANA^[@CR45]^*Anti-CD22 antibodyEpratuzumabA humanized IgG1 monoclonal antibody targeting CD22*EpratuzumabRelapsed or refractory iNHLsPhase 1/2 trial of epratuzumab in indolent non-Hodgkin's lymphoma1/2Completedall, 18%/6%; FL, 24%/8%NA^[@CR52]^EpratuzumabRelapsed or refractory aggressive NHLsPhase 1/2 trial of epratuzumab in patients with recurrent aggressive NHLs1/2Completedall, 10%/6%; DLBCL, 15%/9%NA^[@CR53]^Epratuzumab, rituximabRelapsed or refractory iNHLsPhase 2 trial of rituximab plus epratuzumab in patients with relapsed or refractory, indolent non-Hodgkin's lymphoma2CompletedFL, 54%/24%; SLL, 57%/43%NA^[@CR54]^Epratuzumab, rituximabUntreated FLEpratuzumab and rituximab in treating patients with previously untreated follicular non-Hodgkin's lymphoma2Completed88.2%/42.4%NCT00553501^[@CR55]^Epratuzumab, R-CHOPDLBCLMonoclonal antibody therapy and combination chemotherapy in treating patients with stage II, stage III, or stage IV diffuse large B-cell lymphoma2Completed96%/74%NCT00301821^[@CR56]^*InotuzumabA CD22-targeted ADC combining a humanized IgG4 anti-CD22 monoclonal antibody with calicheamicin, an enediyne antibiotic*Inotuzumab ozogamicin, rituximabB-NHLsStudy evaluating inotuzumab ozogamicin administered in combination with rituximab in subjects with non-Hodgkin's lymphoma1/2CompletedRelapsed FL, 87%/62%; relapsed DLBCL, 74%/50%; refractory aggressive NHLs, 20%/3%NCT00299494^[@CR60]^R-InO vs. RB/RGRelapsed or refractory aggressive NHLsA study of inotuzumab ozogamicin plus rituximab for relapsed or refractory aggressive non-Hodgkin's lymphoma patients who are not candidates for intensive high-dose chemotherapy3TerminatedR-InO, 41%/13%; RB/RG, 44%/13%;NCT01232556^[@CR61]^Inotuzumab ozogamicin, R-CVP vs. R-G-CVPDLBCLTreatment of patients with diffuse large B-cell lymphoma who are not suitable for anthracycline containing chemotherapy2Active, not recruiting--NCT01679119--*Moxetumomab pasudotoxA recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody and a fragment of pseudomonas exotoxin A*Moxetumomab pasudotoxRelapsed or refractory HCLSafety study of moxetumomab pasudotox in patients with HCL with advance disease1Unknown86%/46%NCT00462189^[@CR64]^Moxetumomab pasudotoxRelapsed or refractory HCLMoxetumomab pasudotox for advanced HCL3Completed75%/41%NCT01829711^[@CR65]^*Anti-CD30 antibodySGN-30A chimeric monoclonal antibody consisting of the variable region of an anti-CD30 murine monoclonal antibody with human gamma 1 heavy chain and kappa light chain constant regions*SGN-30Relapsed or refractory HL/ALCLPhase 2 study of SGN-30 in Hodgkin's lymphoma or systemic anaplastic large cell lymphoma2CompletedALCL, 17%/5%; HL, 0%/0%NA^[@CR74]^SGN-30, GVD vs. placebo, GVDRelapsed or refractory classical HLPhase 2 trial of SGN-30 or placebo with GVD in patients with relapsed or refractory classical HL2TerminatedSGN-30, GVD, 65%/NA; GVD, 57%/NANA^[@CR75]^*BVA CD30 ADC connecting an anti-CD30 antibody with the anti-mitotic agent MMAE via a valine-citrulline peptide linker*BVHL/ALCLPhase 1 open-label dose finding study of brentuximab vedotin for CD30^+^ hematologic malignancies1Completed38%/27%NCT00430846^[@CR2]^BVHLA pivotal open-label Trial of brentuximab vedotin for Hodgkin's lymphoma2Completed75%/34%NCT00848926^[@CR79]^BVALCLA phase 2 open-label trial of brentuximab vedotin for systemic anaplastic large cell lymphoma2Completed86%/57%NCT00866047^[@CR80]^BVRelapsed or refractory NHLsA study of brentuximab vedotin in relapsed or refractory non-Hodgkin's lymphoma2CompletedT-NHLs, 41%/24%NCT01421667^[@CR81]^BV vs. methotrexate/bexaroteneCD30^+^ CTCLA phase 3 trial of brentuximab vedotin versus physician's choice (methotrexate or bexarotene) in participants with CD30^+^ cutaneous T-cell lymphoma (ALCANZA study)3CompletedBV, 56%/16%; methotrexate/bexarotene, 13%/2%NCT01578499^[@CR83]^BV, AVD vs. ABVDAdvanced classical HLA frontline therapy trial in participants with advanced classical Hodgkin's lymphoma3Active, not recruitingA+AVD, 86%/73%; ABVD, 83%/70%NCT01712490^[@CR84]^BV, CHP, CHOPCD30^+^ mature T-cell and NK-cell neoplasmsA phase 1 study of brentuximab vedotin given sequentially and combined with multi-agent chemotherapy for CD30^+^ mature T-cell and NK-cell neoplasms1Completedsequential treatment, 85%/62%; combination treatment, 100%/88%NCT01309789^[@CR85],[@CR86]^BV, CHP vs. CHOPCD30^+^ mature T-cell lymphomasECHELON-2: A comparison of brentuximab vedotin and CHP with standard-of-care CHOP in the treatment of patients with CD30^+^ mature T-cell lymphomas3Active, not recruitingBV, CHP, 83%/68%; CHOP, 72%/56%NCT01777152^[@CR87]^*Anti-CD52 antibodyAlemtuzumabA humanized monoclonal antibody targeting CD52*AlemtuzumabRelapsed or refractory CLLPhase 2 trial of slemtuzumab in patients with relapsed or refractory B-cell chronic lymphocytic leukemia exposed to alkylating agents and having failed fludarabine therapy2Completed33%/2%NA^[@CR91]^Alemtuzumab vs. chlorambucilCLLA phase 3 study to evaluate the efficacy and safety of frontline therapy with alemtuzumab vs. chlorambucil in patients with progressive B-cell chronic lymphocytic leukemia3CompletedAlemtuzumab, 83%/24%; chlorambucil, 55%/2%NA^[@CR92]^AlemtuzumabAdvanced MF/SSPhase 2 study of alemtuzumab in patients with advanced mycosis fungoides/Sézary syndrome2Completed55%/32%NA^[@CR93]^AlemtuzumabRelapsed or refractory PTCLA pilot study of alemtuzumab therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphoma2Completed36%/21%NA^[@CR94]^Alemtuzumab, FC vs. FCRCLLFludarabine, cyclophosphamide, and rituximab or alemtuzumab in treating CLL3CompletedFCCam, 90%/19.2%; FCR, 91%/33.75%NCT00564512^[@CR95]^Subcutaneous alemtuzumab, bendamustineRelapsed or refractory CLLBendamustine and subcutaneous alemtuzumab in relapsed or refractory chronic lymphocytic leukemia patients1/2Completed68%/24%NA^[@CR96]^Alemtuzumab, rituximab, pentostatinRelapsed or refractory CLL/SLLPentostatin, alemtuzumab, and rituximab in treating patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma2Completed56%/28%NCT00669318^[@CR97]^Alemtuzumab, CHOPPTCLA phase 2 study of alemtuzumab plus CHOP as frontline chemotherapy for patients with peripheral T-cell lymphoma2Completed80%/65%NA^[@CR98]^Alemtuzumab, CHOPPTCLGITIL trial of alemtuzumab and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma2Completed75%/71%NA^[@CR99]^Alemtuzumab, CHOPPTCLAlemtuzumab, MabCampath® with 2-weekly CHOP chemotherapy for mature T-cell non-Hodgkin's lymphoma2Completed90%/60%NA^[@CR100]^Alemtuzumab, CHOP14 vs.CHOP14PTCLAlemtuzumab and CHOP in T-cell Lymphoma3CompletedALZ-CHOP, NA/52%; CHOP, NA/42%NCT00646854^[@CR101]^alemtuzumab, CHOP14 vs. CHOP14PTCLImmunotherapy in peripheral T-cell lymphoma---the role of alemtuzumab in addition to dose dense CHOP3UnknownALZ-CHOP, NA/60%; CHOP, NA/43%NCT00725231^[@CR102]^*Anti-CD79 antibodypolatuzumab vedotinAn anti-CD79b monoclonal antibody conjugated to MMAE*Polatuzumab vedotin, rituximabRelapsed or refractory B-NHLs/CLLA study of escalating doses of polatuzumab vedotin in participants with relapsed or refractory B-cell non-Hodgkin's lymphoma and chronic lymphocytic leukemia and polatuzumab vedotin in combination with rituximab in participants with relapsed or refractory B-cell non-Hodgkin's lymphoma1Completedsingle-agent polatuzumab vedotin: DLBCL, 56%/16%; iNHLs, 47%/20%; MCL, 100%/0%; CLL, 0%/0%; R-pola: 78%/22%NCT01290549^[@CR106]^Pinatuzumab vedotin, obinutuzumab, polatuzumab vedotin, rituximabRelapsed or refractory DLBCL/FLA study of pinatuzumab vedotin combined with rituximab or polatuzumab vedotin combined with rituximab or obinutuzumab in participants with relapsed or refractory B-cell non-Hodgkin's lymphoma1/2CompletedDLBCL: R-pina, 60%/26%; R-pola, 54%/21%; FL: R-pina, 60%/5%; R-pola, 70%/45%NCT01691898^[@CR107]^Polatuzumab vedotin, rituximab vs. bendamustine, obinutuzumabRelapsed or refractory DLBCL/FLA study of polatuzumab vedotin in combination with rituximab or obinutuzumab plus bendamustine in participants with relapsed or refractory follicular or diffuse large B-cell lymphoma1/2Active, not recruiting--NCT02257567^[@CR108]^Polatuzumab vedotin, R-CHP vs. R-CHOPDLBCLA study comparing the efficacy and safety of polatuzumab vedotin with rituximab-cyclophosphamide, doxorubicin, and prednisone versus rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone in participants with diffuse large B-cell lymphoma3Recruiting--NCT03274492--*Anti-CD19 antibodyInebilizumabA CD19-targeted humanized monoclonal antibody*InebilizumabRelapsed or refractory advanced B-NHLsA phase 1, dose-escalation study of inebilizumab in japanese adult patients with relapsed or refractory advanced B-cell malignancies1CompletedFL, 82%/55%; DLBCL, 50%/17%NCT01957579^[@CR112]^Inebilizumab, rituximabRelapsed or refractory B-NHLsA clinical study using inebilizumab in adult subjects with relapsed or refractory advanced B-cell malignancies1/2CompletedNANCT00983619--Inebilizumab, bendamustine vs. rituximab, bendamustineRelapsed or refractory CLLA phase 2, multicenter, open-label study of inebilizumab in adults with relapsed or refractory chronic lymphocytic leukemia2Completedrituximab, bendamustine 59.7%/6.5%; inebilizumab 2mg/kg, bendamustine 52.8%/5.6%; inebilizumab 4mg/kg, bendamustine 63.9%/11.5%NCT01466153--Inebilizumab, ICE/DHAP vs. rituximab, ICE/DHAPRelapsed or refractory DLBCLA phase 2, multicenter, randomized, open-label study of inebilizumab in adults with relapsed or refractory diffuse large B-cell lymphoma2Completedinebilizumab 2mg/kg, ICE/DHAP, 46.2%/NA; inebilizumab 4mg/kg, ICE/DHAP, 43.6%/NA; rituximab, ICE/DHAP, 47.5%/NANCT01453205--*TafasitamabA novel Fc-engineered, humanized, anti-CD19 antibody with enhanced ADCC*TafasitamabRelapsed or refractory NHLsStudy of Fc-optimized anti-CD19 antibody tafasitamab to treat non-Hodgkin's lymphoma2Active, not recruitingDLBCL, 26%/6%; FL, 29%/9%; iNHLs, 27%/18%NCT01685008^[@CR114]^Tafasitamab, lenalidomideRelapsed or refractory DLBCLA study to evaluate the safety and efficacy of lenalidomide with tafasitamab in patients with relapsed or refractory DLBCL2Active, not recruiting58%/33%NCT02399085^[@CR115]^Tafasitamab, lenalidomideCLL/SLL, PLLPhase 2 tafasitamab in combination with lenalidomide for patients with relapsed or refractory CLL/SLL or PLL or older patients with untreated CLL/SLL or PLL2Active, not recruiting--NCT02005289--Tafasitamab, bendamustine vs. rituximab, bendamustineRelapsed or refractory DLBCLA trial to evaluate the efficacy and safety of tafasitamab with bendamustine versus rituximab with bendamustine in adult patients with relapsed or refractory diffuse large B-cell lymphoma2/3Recruiting--NCT02763319--*Coltuximab ravtansineA CD19-targeted ADC consists of CD19 antibody and a cytotoxic maytansinoid, DM4, which is a potent inhibitor of tubulin polymerization and microtubule assembly*Coltuximab ravtansineRelapsed or refractory DLBCLColtuximab ravtansine as single agent in relapsed or refractory diffuse large B-cell lymphoma patients2Completed43.9%/14.6%NCT01472887^[@CR116]^*loncastuximab tesirineAn ADC consisting of an anti-CD19 humanized monoclonal antibody conjugated to a cytotoxic, crosslinking agent pyrrolobenzodiazepine dimer*loncastuximab tesirineRelapsed or refractory DLBCLStudy to evaluate the efficacy and safety of ioncastuximab tesirine in patients with relapsed or refractory diffuse large B-cell lymphoma2Active, not recruiting--NCT03589469--loncastuximab tesirineRelapsed or refractory B-NHLsStudy of ioncastuximab tesirine in patients with relapsed or refractory B-cell lineage non-Hodgkin's lymphoma1CompletedNANCT02669017--loncastuximab tesirine, ibrutinibDLBCL/MCLSafety and antitumor activity study of loncastuximab tesirine plus ibrutinib in diffuse large B-cell or mantle cell lymphoma1Recruiting--NCT03684694--loncastuximab tesirine, durvalumabDLBCL/MCL/FLSafety and antitumor activity study of loncastuximab tesirine and durvalumab in diffuse large B-cell, mantle cell, or follicular lymphoma1Recruiting--NCT03685344--*Anti-CD37 antibodyOtlertuzumabA humanized variant of SMIP-016 built on the ADAPTIR platform*OtlertuzumabRelapsed or refractory NHL/CLLPhase 1/1b study of otlertuzumab in patients with previously treated CLL or select subtypes of non-Hodgkin's lymphoma1CompletedFL, 12.5%/0%; MCL, 0%/0%; WM, 25%/0%; CLL, 23%/0%NCT00614042^[@CR123],[@CR124]^Otlertuzumab, bendamustine vs. bendamustineRelapsed CLLSafety and efficacy study of otlertuzumab plus bendamustine vs. bendamustine in relapsed chronic lymphocytic leukemia1/2CompletedOtlertuzumab and bendamustin, 69%/9%; bendamustin, 39%/3%NCT01188681^[@CR125]^Otlertuzumab, bendamustine, rituximabRelapsed iNHLsA study of otlertuzumab in combination with rituximab and bendamustine in subjects with relapsed indolent lymphoma1Completed83%/32%NCT01317901^[@CR126]^*IMGN529Consisting of an anti-CD37 antibody coupled with the maytansine-derived anti-microtubule agent, DM1*IMGN529Relapsed or refractory NHLs/CLLIMGN529 in treating patients with relapsed or refractory non-Hodgkin's lymphoma and chronic lymphocytic leukemia1CompletedDLBCL, 22.2%/5.6%; FL, 7.7%/0%; MCL, 0%/0%; MZL, 0%/0%NCT01534715^[@CR129]^*AGS67EA fully human monoclonal IgG2 antibody conjugated via a protease-cleavable linker to MMAE*AGS67ERelapsed or refractory lymphoid malignancyA study to evaluate safety, tolerability, and pharmacokinetics of escalating doses of AGS67E given as monotherapy in subjects with refractory or relapsed lymphoid malignancies1Active, not recruiting--NCT02175433--*BetalutinA novel ARC targeting the CD37 antigen*BetalutinRelapsed or refractory NHLsA Phase 1/2 study of betalutin for treatment of relapsed non-Hodgkin's lymphoma1/2Recruiting--NCT01796171--BetalutinRelapsed or refractory DLBCLStudy of betalutin for treatment of relapsed or refractory non-Hodgkin's lymphoma (LYMRIT-37-05)1Recruiting--NCT02658968--Betalutin, rituximabRelapsed or refractory FLStudy of safety and efficacy of betalutin and rituximab in patients with FL1Recruiting--NCT03806179--*Anti-CCR4MogamulizumabA defucosylated humanized monoclonal antibody directed against CCR4*MogamulizumabATLLPhase 2 study of KW-0761 in subjects with CCR4^+^ adult T-cell leukemia/lymphoma2Completed50%/31%NCT00920790^[@CR138]^Mogamulizumab, mLSG15 vs. mLSG15ATLLMulticenter, randomized, open-label, parallel-group study to compare mLSG15 plus mogamulizumab to mLSG152CompletedMogamulizumab, mLSG15, 86%/52%; mLSG15, 75%/33%NCT01173887^[@CR139]^MogamulizumabPTCLSafety study to evaluate monoclonal antibody mogamulizumab in subjects with peripheral T-cell lymphoma1/2Completed36.8%/7.9%NCT00888927^[@CR140]^MogamulizumabPTCLStudy of mogamulizumab in subjects with CCR4^+^ T-cell lymphoma2Completed35%/14%NCT01192984^[@CR141]^Mogamulizumab vs. vorinostatRelapsed or refractory CTCLStudy of mogamulizumab versus vorinostat in relapsed or refractory CTCL3Active, not recruitingMogamulizumab, 28%/3%; vorinostat, 5%/0%NCT01728805^[@CR142]^*Anti-CD25 antibody*^*90*^*Y-daclizumabA radiolabeled anti-CD25 antibody*^90^Y-daclizumabHL/NHLs^90^Y-Daclizumab to treat Hodgkin's disease, non-Hodgkin's lymphoma and lymphoid leukemia1/2CompletedRelapsed HL, 50%/30%NCT00001575^[@CR145]*90*^*Y-basiliximabA radiolabeled anti-CD25 antibody*^90^Y-basiliximab, BEAMRelapsed or refractory HLRadiolabeled monoclonal antibody therapy and combination chemotherapy before stem cell transplant in treating patients with primary refractory or relapsed Hodgkin's lymphoma1Active, not recruiting--NCT01476839--^90^Y-basiliximab, BEAMMature T-NHLs90Y-basiliximab and combination chemotherapy before stem cell transplant in treating patients with mature T-cell non-Hodgkin's lymphoma1Recruiting--NCT02342782--*Camidanlumab tesitineA CD25 antibody-drug conjugate*Camidanlumab tesitineRelapsed or refractory HL/NHLsStudy of camidanlumab tesitine in patients with relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma1CompletedNANCT02432235--*Anti-CD38 antibodyDaratumumabAn anti-CD38 monoclonal antibody*DaratumumabRelapsed or refractory NKTCL, nasal typeA study to assess the clinical efficacy and safety of daratumumab in participants with relapsed or refractory NK/T-cell lymphoma, nasal type2Active, not recruiting35.7%/0%NCT02927925^[@CR149]^*Anti-CD40 antibodyDacetuzumabA humanized IgG1 monoclonal antibody targeting CD40*DacetuzumabNHLA safety study of dacetuzumab in patients with non-Hodgkin's lymphoma1Completed12%/2%NCT00103779^[@CR152]^DacetuzumabRelapsed DLBCLStudy of dacetuzumab in patients with relapsed diffuse large B-cell lymphoma2Completed9%/4%NCT00435916^[@CR153]^Dacetuzumab, R-ICE vs. placebo, R-ICERelapsed DLBCLA randomized phase 2 placebo-controlled study of R-ICE chemotherapy with and without dacetuzumab for patients with DLBCL2TerminatedDacetuzumab, R-ICE, 66%/33%; placebo, R-ICE, 64%/36%NCT00529503^[@CR154]^*Anti-CD74 antibodymilatuzumabA humanized antibody against CD74*Milatuzumab, veltuzumabRelapsed or refractory B-NHLsVeltuzumab and milatuzumab in treating patients with relapsed or refractory B-cell non-Hodgkin's lymphoma1/2CompletedFL, 33%/7%; DLBCL, 0%/0%; MCL, 17%/0%; MZL, 100%/50%; WM, 0%/0%NCT00989586^[@CR156]^*Anti-CD80 antibodyGaliximabAn anti-CD80 monoclonal antibody*GaliximabRelapsed or refractory HLGaliximab in treating patients with relapsed or refractory Hodgkin's lymphoma2Completed10.3%/NANCT00516217--GaliximabRelapsed or refractory FLPhase 1/2 study of galiximab for relapsed or refractory follicular lymphoma1/2Completed11%/6%--^[@CR159]^Galiximab, rituximabRelapsed or refractory FLSafety and efficacy of galiximab in combination with rituxan in the treatment of non-Hodgkin's lymphoma1/2Completed66%/19%NCT00048555^[@CR160]^*Anti-CD158k antibodyIPH4102An anti-CD158k monoclonal antibody*IPH4102Relapsed or refractory CTCLStudy of IPH4102 in patients with relapsed or refractory cutaneous T-cell lymphoma1Active, not recruiting45%/0%NCT02593045^[@CR165]^IPH4102 vs. IPH4102, gemcitabine, oxaliplatinAdvanced T-NHLsIPH4102 alone or in combination with chemotherapy in patients with advanced T-cell lymphoma2Recruiting--NCT03902184--*Bispecific T cell EngagerBlinatumomabA CD19/CD3 Bispecific T cell Engager*BlinatumomabRelapsed NHLsSafety study of the bispecific T-cell engager blinatumomab in patients with relapsed NHLs1CompletedDLBCL, 55%/36%; MCL, 71%/43%; FL, 80%/40%NCT00274742^[@CR169]^BlinatumomabRelapsed or refractory DLBCLClinical study with blinatumomab in patients with relapsed or refractory diffuse large B-cell lymphoma2Completed43%/19%NCT01741792^[@CR170]^BlinatumomabRelapsed or refractory aggressive B-NHLsStudy to evaluate safety and efficacy of blinatumomab in subjects with relapsed or refractory aggressive B-cell NHL2Active, not recruiting--NCT02910063--*MosunetuzumabA CD20/CD3 Bispecific T cell Engager*MosunetuzumabDLBCLA trial of mosunetuzumab as consolidation therapy in participants with diffuse large B-cell lymphoma following first-line immunochemotherapy and as therapy in participants with previously untreated diffuse large B-cell lymphoma who are unable to tolerate full-dose chemotherapy1/2Recruiting--NCT03677154--Mosunetuzumab, polatuzumab vedotinB-NHLsA study to evaluate the safety and efficacy of mosunetuzumab in combination with polatuzumab vedotin in B-cell non-Hodgkin's lymphoma1Recruiting--NCT03671018--Mosunetuzumab, polatuzumab vedotin, CHP vs.mosunetuzumab, CHOPB-NHLsA phase 1/2 study investigating the safety, tolerability, pharmacokinetics, and efficacy of mosunetuzumab in combination With CHOP or CHP-polatuzumab vedotin in participants With B-cell non-Hodgkin's lymphoma1/2Recruiting--NCT03677141--*RO7082859A CD20/CD3 Bispecific T cell Engager*RO7082859, obinutuzumabRelapsed or refractory B-NHLsA dose escalation study of RO7082859 as a single agent and in combination with obinutuzumab, administered after a fixed, single pre-treatment dose of obinutuzumab in participants with relapsed or refractory B-cell non-Hodgkin's lymphoma1Recruiting--NCT03075696--RO7082859, atezolizumab, obinutuzumabRelapsed or refractory B-NHLsAn open-label phase 1b study of RO7082859 and atezolizumab in adult patients with relapsed or refractory B-cell non-Hodgkin's lymphoma1Recruiting--NCT03533283--RO7082859, obinutuzumab/rituximab, CHOPB-NHLsA study of RO7082859 in combination with rituximab or obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in participants with non-Hodgkin's lymphomas1Recruiting--NCT03467373--*REGN1979A CD20/CD3 Bispecific T cell Engager*REGN1979Relapsed or refractory FLAssess the antitumor activity and safety of REGN1979 in patients with relapsed or refractory follicular lymphoma2Recruiting--NCT03888105--REGN1979B-NHLsA phase 1 study to investigate the safety and tolerability of REGN1979 in patients With CD20^+^ B-cell malignancies1Recruiting--NCT02290951--REGN1979, REGN2810B-NHLsStudy of REGN2810 and REGN1979 in patients with lymphoma1Recruiting--NCT02651662--*XmAb13676A CD20/CD3 Bispecific T cell Engager*XmAb13676B-NHLs, CLL/SLLStudy to evaluate safety and tolerability of XmAb13676 in patients with CD20^−^ expressing hematologic malignancies1Recruiting--NCT02924402--NA: ORR or CR are not available on the clinicaltrials.gov or from the published article although the trial has been completed*iNHLs* indolent NHLs, *CHOP* cyclophosphamide, doxorubicin, vincristine, prednisolone, *CVP* cyclophosphamide, vincristine, and prednisolone, *FC* fludarabine and cyclophosphamide, *G-CHOP* obinutuzumab, cyclophosphamide, doxorubicin, vincristine and prednisone, *G-FC* obinutuzumab, fludarabine and cyclophosphamide, *G-Clb* obinutuzumab and chlorambucil, *R-Clb* rituximab and chlorambucil, *BEAM* carmustine, etoposide, cytarabine, melphalan chemotherapy, *R-CHOP* rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone, *R-InO* rituximab and inotuzumab ozogamicin, *RB* rituximab and bendamustine, *RG* rituximab and gemcitabine, *R-G-CVP* rituximab, gemcitabine, cyclophosphamide, vincristine and prednisolone, *GVD* gemcitabine, vinorelbine, and liposomal doxorubicin, *BV* brentuximab vedotin, *A+AVD* brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine, *ABVD* doxorubicin, bleomycin, vinblastine, and dacarbazine, *CHP* cyclophosphamide, doxorubicin and prednisone, *FCCam* fludarabine cyclophosphamide and alemtuzumab, *FCR* fludarabine cyclophosphamide and rituximab, *CHOP14* cyclophosphamide, doxorubicin, vincristine, and prednisone every 14 days, *ALZ-CHOP* alemtuzumab, cyclophosphamide, doxorubicin, vincristine and prednisone, *R-pola* rituximab and polatuzumab vedotin, *R-pina* rituximab and pinatuzumab vedotin, *R-CHP* rituximab, cyclophosphamide, doxorubicin and prednisone, *ICE* ifosfamide, carboplatin, etoposide, *DHAP* dexamethasone, high-dose cytarabine, cisplatin, *PLL* prolymphocytic leukemia, *mLSG15* a dose-intensified chemotherapy

Obinutuzumab (GA101, Gazyva™) is a humanized type II mAb that can induce ADCC and direct apoptosis both in vitro and in vivo.^[@CR17],[@CR18]^ In a phase 1/2 study (NCT00517530), obinutuzumab as monotherapy showed clinical activity with an acceptable safety profile in aggressive B-NHLs.^[@CR19]^ Moreover, clinical trials (NCT01059630, NCT01332968, and NCT00825149) of obinutuzumab in combination with other chemotherapy regimens showed promising results in relapsed or refractory indolent B-NHLs^[@CR20],[@CR21]^ and untreated follicular lymphoma (FL).^[@CR22]^ The most common nonhematologic AEs were grade 1-2 infusion-related reactions, and the most common hematologic AE was neutropenia. For CLL, the findings of a phase 3 study (NCT01010061) of naïve elderly patients suggested that obinutuzumab in combination with chlorambucil yields better response rates and longer progression-free survival (PFS) than rituximab with chlorambucil and chlorambucil; thus, obinutuzumab became the first drug with "breakthrough therapy designation" approved by the FDA for the treatment of untreated CLL in combination with chlorambucil.^[@CR23]^ Recently, a multicenter, randomized, phase 3 trial (iLLUMINATE, NCT02264574) demonstrated the advantages of obinutuzumab plus ibrutinib over obinutuzumab plus chlorambucil as a first-line treatment for CLL.^[@CR24]^

Ublituximab is another type I, chimeric, recombinant IgG1 mAb targeting a unique epitope on the CD20 antigen, glycoengineered to enhance affinity for all FcRIIIa variants, leading to greater ADCC than other anti-CD20 mAbs such as rituximab and ofatumumab.^[@CR25]^ Ublituximab demonstrated efficacy and safety as a single agent in early clinical trials in patients with B-NHLs and CLL,^[@CR25],[@CR26]^ and it was further investigated in combination regimens. A phase 2 study (NCT02013128) combining ublituximab with ibrutinib was carried out in relapsed or refractory CLL and obtained an overall response rate (ORR) of 88%. Of note, in high-risk patients bearing del17p, del11q, or *TP53* mutations, the ORR was 95%.^[@CR27]^ A phase 3 trial (GENUINE, NCT02301156) of ublituximab plus ibrutinib in high-risk relapsed or refractory CLL reported an ORR of 78% for the combination arm vs 45% for the monotherapy arm.^[@CR28]^ The combination of ublituximab and umbralisib with/without ibrutinib had indicated tolerability and activity in patients with relapsed or refractory B-NHLs and CLL in a phase 1 study (NCT02006485).^[@CR29],[@CR30]^

Other humanized type I anti-CD20 mAbs, such as veltuzumab (IMMU-106) and ocrelizumab (PRO70769), also showed efficacy in patients with relapsed or refractory B-NHLs and FL in phase 1/2 studies (NCT00285428 and NCT02723071).^[@CR31],[@CR32]^ In addition, progress has been made in the study of biosimilars of rituximab. CT-P10 (CELLTRION) was the first mAb biosimilar anticancer drug to gain international regulatory approval following the results of phase 3 trials (NCT02260804 and NCT02162771) in FL.^[@CR33],[@CR34]^ Other examples of rituximab biosimilars include GP2013, PF-05280586, and ABP798. GP2013 has also been approved in the European Union for its efficacy data from a phase 3 trial in FL (ASSIST-FL, NCT01419665).^[@CR35]^ The phase 3 study (NCT02213263) of PF-05280586 displayed positive results as well.^[@CR36]^ Moreover, ABP798 is currently under study (NCT02747043).

Radioimmunotherapy (RIT) has also emerged as an important therapeutic strategy for B-NHLs. Ibritumomab tiuxetan (IDEC-Y2B8, Zevalin®) is a radiolabeled anti-CD20 mAb that targets the same epitope on the CD20 molecule as rituximab. This compound chelates the radioactive particle yttrium-90 (^90^Y), which delivers high beta energy to improve its ability to kill bulky, poorly vascularized tumors.^[@CR37]^ Ibritumomab tiuxetan is effective in both rituximab-naïve and rituximab-resistant FL, as well as in transformed B-NHLs.^[@CR38],[@CR39]^ Consequently, ibritumomab tiuxetan acquired FDA approval for rituximab-naïve relapsed or refractory low-grade B-NHLs and transformed NHLs. The long-term toxicity of developing myelodysplastic syndrome and acute myelogenous leukemia was observed.^[@CR40]^ Furthermore, ibritumomab tiuxetan has shown promising results in the first-line treatment of untreated FL (NCT00772655 and NCT01493479).^[@CR41],[@CR42]^ In addition, a phase 3 trial (FIT, NCT00185393) observed an improvement of efficacy through ibritumomab tiuxetan consolidation;^[@CR43],[@CR44]^ thus, the FDA approved this agent for consolidation therapy in untreated FL patients who achieve partial response (PR) or complete response (CR) after first-line chemotherapy. A phase 3 study of rituximab with or without ibritumomab tiuxetan in untreated FL is ongoing (NCT02320292). Ibritumomab tiuxetan is also being evaluated as consolidation therapy in relapsed or refractory FL in a phase 3 study (NCT01827605). Additionally, ibritumomab tiuxetan combined with high-dose chemotherapy prior to autologous stem cell transplantation (ASCT) has also been proven to be safe with relative efficacy.^[@CR45],[@CR46]^

CD22 {#Sec4}
----

CD22 is a single-spanning membrane glycoprotein with a molecular weight of 140,000 located on the surface of B-cells. It is mostly expressed in mature B-cells and many malignant B-cells.^[@CR47],[@CR48]^ CD22 acts as a negative regulator of B-cell receptor (BCR)-induced signaling and plays a critical role in B-cell activation.^[@CR47],[@CR49]^ The inhibitory function of CD22 and its restricted expression on B-cells make CD22 an ideal target in NHLs.

Epratuzumab is a humanized IgG1 mAb targeting CD22. The crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells.^[@CR50]^ Preclinical studies demonstrated that CD22 mAbs had independent lymphomacidal properties.^[@CR51]^ Single-agent epratuzumab has been investigated in both indolent and aggressive NHLs. In an early phase 1/2 trial including 55 patients with recurrent NHLs, epratuzumab showed a response in FL (ORR 24%), while no response was observed in other indolent lymphomas.^[@CR52]^ In another concurrent phase 1/2 trial, 15% of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) responded to epratuzumab.^[@CR53]^ The combination of epratuzumab with rituximab has been tested in a multicenter phase 2 trial and exhibited an ORR of 54% in FL and 57% in small lymphocytic lymphoma (SLL).^[@CR54]^ Epratuzumab plus rituximab was also studied in untreated FL and obtained an ORR of 88.2% (NCT00553501).^[@CR55]^ In aggressive lymphomas, a phase 2 trial (NCT00301821) showed that epratuzumab combined with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) achieved an ORR of 96% in DLBCL, with 3-year event-free survival (EFS) and OS rates of 70% and 80%, respectively.^[@CR56]^

Conjugate antibodies utilize the direct conjugation of mAbs with cytotoxic agents, and there are two types of antibody-based conjugates: antibody-drug conjugates (ADCs) and immunotoxins.^[@CR57]^ ADCs are mAbs connected to bioactive drugs by chemical linkers. Inotuzumab ozogamicin (InO, CMC-544) is a CD22-targeted ADC combining a humanized IgG4 anti-CD22 mAb with calicheamicin, an enediyne antibiotic, which causes DNA damage and cell apoptosis.^[@CR58],[@CR59]^ The combination of InO with rituximab in a phase 1/2 study (NCT00299494) of relapsed FL, DLBCL, and refractory aggressive NHL induced ORRs of 87%, 74%, and 20%, respectively. The most common grade 3--4 AEs were thrombocytopenia (31%) and neutropenia (22%).^[@CR60]^ However, InO plus rituximab failed to obtain positive results in a randomized phase 3 trial (NCT01232556) of relapsed or refractory CD22^+^ aggressive B-NHLs and FLs.^[@CR61]^ A phase 2 trial (NCT01679119) of InO plus rituximab, cyclophosphamide, vincristine, and prednisolone (R-CVP) in chemotherapy-naïve DLBCL not suitable for anthracycline-based treatment is ongoing. An immunotoxin is a genetically engineered protein consisting of a targeting portion linked to a toxin. Moxetumomab pasudotox connects anti-CD22 to PE38, a fragment of Pseudomonas exotoxin A, and induces apoptosis through the inhibition of protein synthesis.^[@CR62],[@CR63]^ A phase 1 study (NCT00462189) demonstrated an ORR of 86% in hairy cell leukemia (HCL) patients with no dose-limiting toxicity.^[@CR64]^ Moreover, a pivotal phase 3 study (NCT01829711) for relapsed or refractory HCL obtained an ORR of 75%, with a CR rate of 41%.^[@CR65]^ The FDA approved moxetumomab pasudotox (Lumoxiti) for the treatment of adult patients with relapsed or refractory HCL.

CD30 {#Sec5}
----

CD30 is a 120-kDa type I transmembrane receptor of the tumor necrosis factor receptor (TNFR) superfamily.^[@CR66]^ The binding of CD30 with its ligand induces signal transduction through several downstream pathways, especially nuclear factor-κB (NF-κB).^[@CR67]^ CD30 is normally expressed on activated B cells, T cells, and NK cells, as well as virally infected lymphocytes. In addition, CD30 is universally expressed in HL and anaplastic large cell lymphoma (ALCL).^[@CR68],[@CR69]^ Other lymphoproliferative disorders, such as DLBCL, primary mediastinal B-cell lymphoma (PMBCL), peripheral T-cell lymphoma (PTCL), mycosis fungoides (MF), Sézary syndrome (SS) and adult T-cell leukemia/lymphoma (ATLL), can also express CD30 to various degrees.^[@CR70]--[@CR72]^

A chimeric mAb SGN-30, consisting of the variable region of an anti-CD30 murine mAb with human gamma 1 heavy chain and kappa light chain constant regions, promotes growth arrest and DNA fragmentation in vitro and exhibits antitumor activity in HL models.^[@CR73]^ In a phase 2 study of relapsed or refractory HL or ALCL, SGN-30 showed only a modest effect in ALCL (2 CR and 5 PR in 41 ALCL patients).^[@CR74]^ However, another phase 2 trial used a combination of SGN-30 with gemcitabine, vinorelbine, and liposomal doxorubicin in relapsed HL and showed an ORR of 65%, while grades 3--5 pneumonitis occurred in five patients, leading to the premature closure of the trial.^[@CR75]^

Brentuximab vedotin (BV, Adcetris), a CD30 ADC, connects an anti-CD30 antibody with the anti-mitotic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide-linker. It showed strong activity against CD30^+^ tumor cell lines in vitro, as well as xenograft models of HL and ALCL.^[@CR76]^ A phase 1 dose-escalation study (NCT00430846) of BV in 45 patients with relapsed or refractory CD30^+^ hematological malignancies (mainly HL) determined the optimal dose of BV as 1.8 mg/m^2^ intravenously every 3 weeks and showed an ORR of 38%.^[@CR2]^ Common AEs of BV include fatigue, pyrexia, diarrhea, nausea, peripheral neuropathy, neutropenia, anemia, and arthralgias.^[@CR2]^ Other AEs, such as anaphylaxis and acute pancreatitis, have also been reported.^[@CR77],[@CR78]^ BV was granted FDA accelerated approval for the treatment of relapsed or refractory HL and ALCL based on the results of two phase 2 studies. NCT00848926 enrolled 102 relapsed or refractory HL patients and obtained an ORR of 75% (CR 34%) with a median duration of response (DoR) of 6.7 months.^[@CR79]^ NCT00866047 showed an ORR of 86% (CR 57%) with a median DoR of 12.6 months in 58 patients with relapsed or refractory CD30^+^ ALCL.^[@CR80]^ After approval, the FDA issued a boxed warning related to the risk of progressive multifocal leukoencephalopathy and added a contraindication warning for the concomitant use of BV and bleomycin due to pulmonary toxicity.

In addition to ALCL, BV has shown efficacy as a single agent in other T-NHLs (NCT01421667).^[@CR81]^ In addition to systemic lymphomas, BV was also utilized in primary CD30^+^ cutaneous lymphomas and showed encouraging efficacy.^[@CR82]^ A phase 3 randomized multicenter trial (ALCANZA, NCT01578499) was conducted to evaluate single-agent BV vs a control arm of the investigator's choice of standard therapies in patients with CD30^+^ primary cutaneous ALCL or MF. ALCANZA demonstrated an improvement in ORR (ORR: 56.3% in the BV arm vs. 12.5% in the conventional therapy arm),^[@CR83]^ leading to FDA approval for the treatment of adult patients with primary cutaneous ALCL or CD30^+^ MF.

For BV combined with chemotherapy, in a multicenter phase 3 trial (NCT01712490) involving patients with untreated stage III or IV HL, patients were randomized to receive BV, doxorubicin, vinblastine, and dacarbazine (A+AVD) or doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). The results showed that at a median follow-up of 24.6 months, the 2-year modified PFS rates in the A+AVD and ABVD groups were 82.1% and 77.2%, respectively. Neutropenia and peripheral neuropathy were the most common AEs.^[@CR84]^ Based on these promising clinical data, the FDA expanded the approval of BV for the first-line treatment of stage III or IV HL in combination with chemotherapy. A phase 1 study (NCT01309789) combining BV with cyclophosphamide, doxorubicin, and prednisolone in patients with CD30^+^ PTCL resulted in an objective response in all patients (CR 88%).^[@CR85]^ Moreover, the five-year follow-up demonstrated durable remission in half of the patients after combination therapy.^[@CR86]^ Therefore, a randomized phase 3 trial (ECHELON-2, NCT01777152) comparing BV plus cyclophosphamide, doxorubicin and prednisone (CHP) with CHOP was conducted in untreated patients and demonstrated a significant improvement in PFS and OS with a manageable safety profile when using BV plus CHP.^[@CR87]^ The FDA thus approved BV in combination with chemotherapy for adults with untreated ALCL or other CD30^+^ PTCL.

CD52 {#Sec6}
----

The CD52 antigen is a small glycopeptide highly expressed on normal and malignant B and T lymphocytes. The exact function of CD52 remains undefined, but in vitro studies have proven that it is a costimulatory molecule for the induction of CD4^+^ regulatory T-cells.^[@CR88]^

Alemtuzumab (Campath®) is a humanized mAb targeting CD52 that can induce complement-mediated lysis as well as caspase-independent cell death in malignant lymphoid cells.^[@CR89],[@CR90]^ Single-agent alemtuzumab received accelerated approval by the FDA for CLL patients who had received alkylating agents and failed fludarabine therapy.^[@CR91]^ A phase 3 randomized trial comparing alemtuzumab to chlorambucil as first-line treatment showed significantly improved PFS, time to alternative treatment, ORR and CR, with manageable toxicity in CLL.^[@CR92]^ Alemtuzumab has also been evaluated as monotherapy in T-NHLs and exhibited efficacy in advanced MF, Sézary syndrome (SS), and relapsed or refractory PTCL,^[@CR93],[@CR94]^ where hematological toxicity and cytomegalovirus (CMV) reactivation were the most common AEs.

Alemtuzumab-containing chemoimmunotherapy regimens can be effective but have been limited by their toxicities in CLL (NCT00564512).^[@CR95]^ The bendamustine and subcutaneous alemtuzumab combination was proven to be as effective as the combination of fludarabine, cyclophosphamide, and cladribine and was safe in heavily pretreated and elderly patients.^[@CR96]^ Other attempts at combining pentostatin, alemtuzumab, and low-dose rituximab (NCT00669318) also yielded efficacy and tolerability in relapsed or refractory 17p13-deleted CLL.^[@CR97]^ The combination of alemtuzumab and CHOP-based chemotherapy was explored in untreated PTCL.^[@CR98]--[@CR100]^ Phase 3 randomized studies (NCT00646854 and NCT00725231) of alemtuzumab plus CHOP in either young or elderly PTCL patients achieved improved PFS or OS.^[@CR101],[@CR102]^

CD79 {#Sec7}
----

CD79, composed of CD79A and CD79B components, is a main BCR signaling component and is expressed almost exclusively on B-cells and B-NHLs. CD79 expression precedes immunoglobulin heavy-chain gene rearrangement and CD20 expression during B-cell development but disappears in the late stage of B-cell differentiation.^[@CR103]^ When BCR is cross-linked, CD79 is targeted to a lysosome-like compartment^[@CR104]^ and induces cell apoptosis or triggers cell activation and division with rescue signals from T cells.^[@CR105]^ Therefore, CD79 has become an attractive target for the use of ADCs, and preclinical studies found two stable-linker ADCs capable of killing NHL cell lines in vitro and in xenograft models.^[@CR106]^

Polatuzumab vedotin (DCDS4501A) is an anti-CD79B mAb conjugated to MMAE. In a phase 1 study (NCT01290549) in relapsed or refractory B-NHLs and CLL, no objective response was observed in CLL, while at the recommended phase 2 dose of 2.4 mg/kg, objective responses were obtained in 23 of 42 patients with NHLs by polatuzumab vedotin monotherapy (56% in patients with DLBCL, 47% with indolent NHLs, and 100% with mantle cell lymphoma (MCL)) and in 7 of 9 patients by polatuzumab vedotin plus rituximab.^[@CR106]^ Polatuzumab vedotin was further evaluated in a phase 2 trial (NCT01691898) in combination with rituximab in patients with relapsed or refractory NHLs. The results showed that the ORRs and CR rates were 54% and 21% in DLBCL and 70% and 45% in FL, respectively. Grade ≥3 AEs occurred in 77% of DLBCL patients and 50% of FL patients, mainly as neutropenia, anemia, and diarrhea.^[@CR107]^ Furthermore, the findings of a phase 2 study (NCT02257567) pointed out that adding polatuzumab vedotin to bendamustine and rituximab (BR) treatment improved survival in patients with relapsed or refractory DLBCL.^[@CR108]^ The combination of polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP) vs R-CHOP in DLBCL is currently being investigated in a phase 3 study (POLARIX, NCT03274492).

CD19 {#Sec8}
----

CD19 is a B-cell-specific member of the immunoglobulin superfamily that augments signals by the pre-BCR/BCR and modulates B-cell fate decisions at multiple stages of development.^[@CR109]^ CD19 is highly expressed in nearly all B-NHLs, making it an excellent target for immune-based therapies.^[@CR110]^

Inebilizumab (MEDI-551) is a CD19-targeted humanized mAb that has potent ADCC activity in vitro and in vivo in preclinical studies.^[@CR111]^ Inebilizumab monotherapy has been evaluated in phase 1 studies and showed acceptable toxicity and promising efficacy in patients with relapsed or refractory FL and DLBCL (NCT01957579).^[@CR112]^ A phase 1/2 trial (NCT00983619) of inebilizumab alone and in combination with rituximab in FL, CLL, and DLBCL has recently been completed. Regarding inebilizumab in combination with chemotherapy, recent clinical trials did not yield promising results. A phase 2 trial (NCT01466153) comparing inebilizumab plus bendamustine and BR did not find any significant difference in the ORR between the two groups. Another randomized phase 2 study (NCT01453205) on rituximab plus ifosfamide, carboplatin, and etoposide (ICE)/dexamethasone, high-dose cytarabine, and cisplatin (DHAP) vs inebilizumab plus ICE/DHAP in patients with relapsed or refractory DLBCL did not show any significant difference in ORR, PFS, or OS.

Tafasitamab (MOR208, XmAb®5574) is a novel Fc-engineered, humanized, anti-CD19 antibody with enhanced ADCC, antibody-dependent cellular phagocytosis and apoptosis, as well as more potent antitumor activity in vivo than its IgG1 analog.^[@CR113]^ These effects were achieved by increasing the affinity for FcγRIIIa on effector cells through the introduction of S239D and I332E amino acid substitutions to the Fc domain. Tafasitamab monotherapy exhibited promising clinical activity in patients with relapsed or refractory B-NHLs with a favorable safety profile. The ORRs were 26%, 29%, and 27% in DLBCL, FL, and other indolent NHLs, respectively, with 9% of patients experiencing grade 3--4 neutropenia (NCT01685008).^[@CR114]^ Furthermore, combinations with lenalidomide and bendamustine are being evaluated in recent phase 2/3 clinical trials (NCT02399085, NCT02005289, and NCT02763319). Based on the preliminary data from a phase 2 study (L-MIND, NCT02399085) in combination with lenalidomide, this mAb was granted FDA breakthrough therapy and fast track designations for DLBCL. Eighty-one patients enrolled in the L-MIND study obtained an ORR of 58%, including 33% CR, with no unexpected toxicities observed. With a median follow-up of 12 months, the median PFS was 16.2 months.^[@CR115]^

In addition, the CD19-targeted ADC coltuximab ravtansine (SAR3419) consists of a cytotoxic maytansinoid, DM4, which is a potent inhibitor of tubulin polymerization and microtubule assembly. In a phase 2 study (NCT01472887), this agent showed good tolerance and moderate clinical responses in pretreated patients with relapsed or refractory DLBCL (ORR 43.9%).^[@CR116]^ A novel ADC based on coltuximab ravtansine showed promising preclinical data and may become an attractive candidate for clinical investigation.^[@CR117]^

Loncastuximab tesirine (ADCT-402) is a novel CD19-targeted ADC that delivers SG3199, a highly cytotoxic pyrrolobenzodiazepine dimer, and showed highly targeted cytotoxicity in vitro and antitumor activity in vivo in preclinical studies.^[@CR118]^ A pivotal phase 2 study (NCT03589469) is currently ongoing on relapsed or refractory DLBCL, as well as phase 1 studies (NCT02669017, NCT03684694, and NCT03685344) on relapsed or refractory B-NHLs.

CD37 {#Sec9}
----

CD37 is a heavily glycosylated transmembrane protein of the tetraspanin superfamily and represents one of the specific proteins for normal and malignant mature B-cells. The expression of CD37 is detected in CLL, Burkitt lymphoma (BL), MCL, and FL,^[@CR119],[@CR120]^ and it is involved in various biological processes, such as cell adhesion, proliferation, differentiation, intercellular communication via exosomes and immune response.^[@CR121]^

Small modular immunopharmaceuticals (SMIPs) are disulfide-linked single-chain proteins comprised of one antigen-binding region (V~H~/V~L~), a hinge, and an Fc domain of the human IgG1 region (CH2-CH3). Due to their smaller size, SMIPs may have better tissue penetration than mAbs. SMIP-016 is a homodimeric protein specially engineered to exhibit the full binding activity of an anti-CD37 antibody. Preclinical studies have demonstrated that SMIP-016 can induce apoptosis and ADCC in B-cell leukemia/lymphoma cell lines and primary CLL cells.^[@CR122]^

Otlertuzumab (TRU-016) is a humanized variant of SMIP-016 built on the ADAPTIR (modular protein technology) platform. In a phase 1 study (NCT00614042), otlertuzumab was well tolerated and exhibited modest activity as monotherapy in CLL and select subtypes of relapsed or refractory NHLs. The ORR was 23% in CLL, with the most frequent grade ≥3 AEs being thrombocytopenia, neutropenia, anemia, fatigue, and hypophosphatemia.^[@CR123]^ For patients with relapsed or refractory FL, MCL, and Waldenström's macroglobulinemia (WM), a lymph node reduction of 50% or more was observed in 3 of 12 patients.^[@CR124]^ The efficacy of this agent can be enhanced in combination with chemotherapy. A randomized phase 2 trial (NCT01188681) showed a significantly increased response rate and prolonged PFS of otlertuzumab in combination with bendamustine over single-agent bendamustine in relapsed CLL. The ORR of this combination therapy was 69%, with a median PFS of 15.9 months.^[@CR125]^ Similarly, a phase 1 study (NCT01317901) combining otlertuzumab with BR in relapsed or refractory B-NHLs showed promising activity with no unexpected toxicity. The ORR was 83% (CR 32%).^[@CR126]^

Anti-CD37 ADCs such as IMGN529 and AGS67E were also studied. IMGN529 couples an anti-CD37 antibody with the maytansine-derived anti-microtubule agent, DM1. IMGN529 has exhibited potent antitumor activity in preclinical models of CD37^+^ NHLs.^[@CR127],[@CR128]^ A phase 1 trial (NCT01534715) of IMGN529 in relapsed or refractory NHLs and CLL has recently been reported, showing manageable safety profiles and preliminary evidence of activity, particularly in DLBCL.^[@CR129]^ AGS67E is a fully human monoclonal IgG2 antibody conjugated via a protease-cleavable linker to MMAE. AGS67E has shown remarkable preclinical antitumor effects in NHLs and CLL cell lines and patient-derived xenograft models.^[@CR130]^ Clinically, a phase 1 study (NCT02175433) of escalating doses of AGS67E as monotherapy in relapsed or refractory lymphoid malignancies is ongoing.

^177^Lu-lilotomab satetraxetan (^177^Lu-DOTA-HH1, Betalutin®) is a novel antibody radionuclide conjugate (ARC) targeting the CD37 antigen. This agent received fast channel assignment from the FDA based on the preliminary data of efficacy and safety in a phase 1/2 trial (LYMRIT 37-01, NCT01796171) in relapsed or refractory FL. It is currently in a pivotal phase 2 trial (PARADIGME) in third-line rituximab-resistant FL, while also being investigated as a single agent in a phase 1 study (NCT02658968) in relapsed or refractory DLBCL and in combination with rituximab in a phase 1 study (NCT03806179) in second-line FL treatment.

C-C chemokine receptor type 4 {#Sec10}
-----------------------------

C-C chemokine receptor type 4 (CCR4) is a seven-transmembrane G-protein-coupled receptor principally expressed on Th2 cells and CD4^+^ regulatory T cells,^[@CR131],[@CR132]^ as well as in various types of PTCLs, including MF and ATLL.^[@CR133],[@CR134]^ Furthermore, CCR4 expression was found to be an independent and significant unfavorable prognostic factor in these diseases,^[@CR133],[@CR134]^ which makes it a promising target in the treatment of PTCL and ATLL.

Mogamulizumab (KW-0761, Poteligeo) is the first defucosylated humanized mAb directed against CCR4; it has been proven to induce ADCC against CCR4^+^ malignant T cells^[@CR135]^ and to reduce CCR4^+^ Treg cell numbers in cutaneous T-cell lymphoma (CTCL).^[@CR136],[@CR137]^ Mogamulizumab was first approved for relapsed or refractory ATLL due to its promising efficacy (ORR 50%) and acceptable toxicities in a phase 2 study (NCT00920790).^[@CR138]^ In a randomized phase 2 study (NCT01173887) of dose-intensified chemotherapy with or without mogamulizumab in untreated aggressive ATLL, the mogamulizumab-containing arm showed a higher CR rate with manageable toxicities.^[@CR139]^ In addition to its application in ATLL, the efficacy of mogamulizumab in CTCL has also been confirmed. A phase 1/2 study (NCT00888927) of mogamulizumab was performed on 41 pretreated patients with CTCL and resulted in an ORR of 36.8% (47.1% in SS and 28.6% in MF). The most common AEs were nausea, chills, and infusion-related reactions.^[@CR140]^ A multicenter phase 2 study (NCT01192984) of relapsed CCR4^+^ PTCL and CTCL patients in Japan obtained an ORR of 35% and a median PFS of 3 months. Lymphocytopenia, leukocytopenia, and neutropenia (19%) were the most common grade 3-4 AEs.^[@CR141]^ Therefore, mogamulizumab was first approved for untreated ATLL as well as relapsed or refractory PTCL in Japan.

The final results of a phase 3, randomized, multicenter clinical trial of mogamulizumab vs vorinostat in previously treated CTCL (MAVORIC, NCT01728805) have been reported.^[@CR142]^ The study included 372 patients and was the largest randomized trial in CTCL. Mogamulizumab resulted in a longer PFS than vorinostat (median 7.7 months vs. 3.1 months). The most common AEs of mogamulizumab were pyrexia and cellulitis. Mogamulizumab was granted approval in the European Union and the United States for the treatment of adult patients with relapsed or refractory MF or SS after at least one prior systemic therapy.^[@CR143]^

Other surface antigens {#Sec11}
----------------------

### CD25 {#Sec12}

CD25 (IL2R-α) is expressed on both HL and various NHLs and has been studied as a therapeutic target for over two decades. Denileukin diftitox (DD, ONTAK), a diphtheria exotoxin conjugated to an IL-2 fragment, was granted full FDA approval for the treatment of CTCL.^[@CR144]^ Although the efficacy of the anti-CD25 antibodies basiliximab and daclizumab is limited, radiolabeled antibodies are promising. ^90^Y-daclizumab achieved responses in 50% of patients with relapsed HL (NCT00001575).^[@CR145]^ ^90^Y-basiliximab is being evaluated in combination with carmustine, etoposide, cytarabine, melphalan (BEAM) chemotherapy for ASCT in relapsed or refractory HL (NCT01476839), as well as T-NHLs (NCT02342782). Camidanlumab tesirine (ADCT-301), a CD25 ADC, has been investigated in a phase 1 trial (NCT02432235) in patients with CD25^+^ relapsed or refractory HL and NHLs.

### CD38 {#Sec13}

The CD38 antigen is a type II transmembrane glycoprotein with receptor and enzyme functions that is expressed in a number of hematological malignancies, particularly in multiple myeloma (MM).^[@CR146]^ In addition, its expression has also been reported in lymphomas such as MCL^[@CR147]^ and NK/T-cell lymphoma (NKTCL).^[@CR148]^ Daratumumab is a CD38 mAb approved for treating relapsed or refractory and untreated MM. In a phase 2 study (NCT02927925) of daratumumab in relapsed or refractory NKTCL, the ORR was 35.7% in 16 patients.^[@CR149]^

### CD40 {#Sec14}

CD40 is a type-I transmembrane protein that belongs to the TNFR family. CD40 is expressed on B cells, monocytes, dendritic cells, endothelial cells and epithelial cells and plays a critical role in the regulation of immune responses.^[@CR150]^ In addition, CD40 is expressed on B-NHLs, leading to the modulation of tumor cell growth after binding with its natural ligand (CD40L).^[@CR151]^ Dacetuzumab (SGN-40) is a humanized IgG1 mAb targeting CD40. Although dacetuzumab has previously demonstrated anti-lymphoma activity in a phase 1 study (NCT00103779),^[@CR152]^ single-agent dacetuzumab showed only modest activity in patients with relapsed DLBCL (NCT00435916)^[@CR153]^ and failed to obtain higher CR rates when combined with rituximab plus ICE (R-ICE) in relapsed DLBCL in a phase 2 study (NCT00529503).^[@CR154]^

### CD74 {#Sec15}

The humanized antibody milatuzumab (hLL1) is a mAb against CD74, which is involved in malignant B-cell proliferation and survival. Preclinical studies found that milatuzumab had promising antitumor activity in NHL in vitro and in tumor xenograft models.^[@CR155]^ Moreover, a phase 1/2 study (NCT00989586) delivered the anti-CD20 mAb veltuzumab (200 mg/m^2^ weekly) and escalating doses of milatuzumab to relapsed or refractory B-NHL patients and reported an ORR of 24% and a median DoR of 12 months.^[@CR156]^ Another preclinical study of the novel bispecific hexavalent Abs (HexAbs) veltuzumab and milatuzumab demonstrated enhanced antitumor activity in cell lines or primary patient samples of MCL and other CD20^+^/CD74^+^ malignancies.^[@CR157]^

### CD80 {#Sec16}

CD80 (B7-1), a cell-surface receptor, is implicated in the costimulation of T-cell function and expressed on B-NHLs. The anti-CD80 mAb galiximab (IDEC-114) can inhibit tumor cells of B-NHLs in vitro and in mouse models, either alone or combined with chemotherapy (fludarabine or doxorubicin).^[@CR158]^ A phase 2 study (NCT00516217) evaluated galiximab in relapsed or refractory HL and reported an ORR of 10.3%. Moreover, a phase 1/2 study on galiximab in relapsed or refractory FL revealed an ORR of 11% (CR 6%).^[@CR159]^ Another phase 1/2 trial (NCT00048555) of galiximab and rituximab reported an ORR of 66% (CR 19% and unconfirmed complete remission (CRu) 14%) in relapsed or refractory FL with rituximab-refractory patients excluded.^[@CR160]^

### CD158k {#Sec17}

CD158k (KIR3DL2) is a member of the highly polymorphic family of killer-cell immunoglobulin-like receptors (KIRs) and is expressed on NK cells and a small proportion of CD8^+^ T cells, as well as CD4^+^ T cells in CTCL.^[@CR161]--[@CR163]^ The anti-CD158k mAb IPH4102 has been found to be potent and safe in preclinical studies.^[@CR164]^ A phase 1 study (NCT02593045) demonstrated efficacy and safety in CTCL,^[@CR165]^ with the expansion study ongoing. In addition, a phase 2 study (NCT03902184) of IPH4102 alone or in combination with chemotherapy is recruiting patients with advanced T-NHLs.

### Bispecific T cell Engagers {#Sec18}

Bispecific T cell Engagers (BiTEs) are engineered bispecific anti-CD3 antibodies consisting of the variable domains of two antibodies linked in a single chain. A BiTE antibody binds both CD3^+^ cytotoxic T cells and a target antigen to bring the two cells into proximity and thus triggers T cells to kill tumor cells via perforin-mediated apoptosis.^[@CR166]^ Blinatumomab is a CD19/CD3 BiTE that shows remarkable anti-lymphoma activity both in vitro and in vivo.^[@CR167],[@CR168]^ In a phase 1 dose-escalation study (NCT00274742) in patients with relapsed or refractory NHLs, 60 μg/m^2^/day was established as the maximum tolerated dose, with 22% of patients experiencing grade 3 neurologic events. For patients treated at 60 μg/m^2^/day, the ORR was 69% (DLBCL, 55%; MCL, 71%; FL, 80%), with a median DoR of 404 days.^[@CR169]^ In another phase 2 study (NCT01741792) in patients with relapsed or refractory DLBCL comparing weekly step-up dosing with flat dosing, the ORR was 43%. However, neurological AEs are also common.^[@CR170]^ A later phase 2 trial (NCT02910063) of blinatumomab in aggressive B-NHLs is ongoing.

In addition, trials on anti-CD20/CD3 bispecific antibodies, including mosunetuzumab (BTCT4465A, NCT03677154, NCT03671018 and NCT03677141), RO7082859 (NCT03075696, NCT03533283 and NCT03467373), REGN1979 (NCT03888105, NCT02290951, and NCT02651662) and XmAb13676 (NCT02924402) are currently ongoing.

In summary, therapies targeting the lymphoma surface antigen have made great progress. In general, mAbs are effective in the treatment of lymphoma, as evidenced by the FDA accelerated approval of many drugs. Moreover, mAbs as monotherapy have fewer adverse reactions and higher tolerance than conventional chemotherapy. However, mAbs also have limitations, such as off-target effects. In the future, more research on the precise mechanisms of the efficacy and resistance of mAbs is needed. The design of future clinical trials should focus on subgroups with specific pathogenic mechanisms. At the same time, attention should also be paid to the timing, duration, and dose optimization of mAbs, either alone or in combination with traditional chemotherapy.

Signaling transduction pathways and targeted therapies {#Sec19}
======================================================

Signaling transduction pathways are critically involved in lymphoma progression. Inhibitors targeting key pathways, including spleen tyrosine kinase (SYK), Bruton's tyrosine kinase (BTK), phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR), Janus kinase-signal transducer and activator of transcription (JAK-STAT), NOTCH, NF-κB and ubiquitin-proteasome pathway (UPP), have been applied to treat lymphomas.

SYK {#Sec20}
---

SYK, a nonreceptor tyrosine kinase, plays an important role in BCR and T-cell receptor (TCR) signaling. The phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) in the Igα (CD79A)/Igβ (CD79B) cytoplasm region recruits SYK and induces SYK activation, BTK recruitment, and phospholipase Cγ2 (PLCγ2) activation.^[@CR171]^ In TCR signaling, phosphorylated CD3 and ζ subunits of the TCR complex by the Src-related kinases LCK and FYN recruit zeta-chain-associated protein kinase 70 (ZAP-70) and SYK (Fig. [1](#Fig1){ref-type="fig"}).^[@CR172]^Fig. 1Signaling transduction pathways in lymphoma cells

The activated B cell-like subtype of DLBCL (ABC-DLBCL) is characterized by antigen-driven BCR signaling,^[@CR173],[@CR174]^ while germinal center B cell-like (GCB)-DLBCL features tonic, antigen-independent BCR signaling.^[@CR175],[@CR176]^ BL is also characterized by tonic BCR signaling and mostly relies on SYK.^[@CR177]^ In T-NHLs, aberrant SYK expression was reported in monomorphic epitheliotropic intestinal T-cell lymphomas (MEITL, type II EATL),^[@CR178]^ the follicular variant of PTCL, not otherwise specified (PTCL-NOS), and angioimmunoblastic T-cell lymphoma (AITL) due to t(5;9)(q33;q22) *ITK*/*SYK* translocation.^[@CR179]--[@CR181]^

The targeted agents and clinical trials related to SYK and BTK are listed in Table [2](#Tab2){ref-type="table"}. Fostamatinib disodium, the first approved oral SYK inhibitor, was evaluated in a phase 1/2 trial (NCT00446095) of recurrent B-NHLs, showing an ORR of 22% in DLBCL, 10% in FL, and 11% in MCL.^[@CR182]^ TAK-659 is being studied in a phase 2 trial in relapsed or refractory DLBCL (NCT03123393) alone, in combination with venetoclax in NHLs in a phase 1 trial (NCT03357627), and in combination with R-CHOP in DLBCL in a phase 1 trial (NCT03742258). The efficacy of entospletinib (GS-9973) is being explored in a phase 2 trial (NCT01799889) in relapsed or refractory hematologic malignancies alone as well as in combination with obinutuzumab in a phase 1/2 trial in NHLs (NCT03010358). Another phase 2 study (NCT01796470) of entospletinib combined with idelalisib in relapsed or refractory NHLs and CLL underwent early termination due to treatment-emergent pneumonitis in 18% of patients.^[@CR183]^ Cerdulatinib (PRT-062070), a dual SYK/JAK inhibitor, was reported to have a greater capacity to suppress cell proliferation and induce apoptosis than PRT-060318, an SYK-selective inhibitor, in ATLL-derived cell lines and murine models.^[@CR184]^ A phase 1/2 trial (NCT01994382) of cerdulatinib in NHLs and CLL/SLL and a phase 2 trial (NCT04021082) of cerdulatinib in relapsed or refractory PTCL are ongoing.Table 2Targeted drugs and clinical trials related to SYK and BTKDrugDiseaseTrial namePhaseStatusORR/CRNCT\#Reference*SYK inhibitorFostamatinibA SYK inhibitor*FostamatinibRelapsed or refractory B-NHLsEfficacy and safety study of fostamatinib tablets to treat B-cell lymphoma1/2CompletedDLBCL, 22%; FL, 10%; MCL, 11%NCT00446095^[@CR182]^*TAK-659A SYK inhibitor*TAK-659Relapsed or refractory DLBCLTAK-659 in participants with relapsed or refractory diffuse large B-cell lymphoma2Active, not recruiting--NCT03123393--TAK-659, venetoclaxRelapsed or refractory NHLA study of TAK-659 in combination with venetoclax for adult participants with previously treated non-Hodgkin's lymphoma1Active, not recruiting--NCT03357627--TAK-659, R-CHOPHigh-risk DLBCLCombination chemotherapy and TAK-659 as frontline treatment in treating patients with high-risk diffuse large B-cell lymphoma1Recruiting--NCT03742258--*EntospletinibA SYK inhibitor*EntospletinibRelapsed or refractory hematologic malignanciesEntospletinib in adults with relapsed or refractory hematologic malignancies2Active, not recruiting--NCT01799889--Entospletinib, obinutuzumabRelapsed or refractory CLL/SLL, NHLEntospletinib and obinutuzumab in treating patients with relapsed chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkin's lymphoma1/2Recruiting--NCT03010358--Entospletinib, idelalisibRelapsed or refractory hematologic malignanciesEntospletinib in combination with idelalisib in adults with relapsed or refractory hematologic malignancies2Terminated--NCT01796470^[@CR183]^*CerdulatinibA dual SYK/JAK inhibitor*CerdulatinibCLL/SLL, NHLPhase 1/2 dose-escalation study in CLL/SLL or NHL1/2Recruiting--NCT01994382--CerdulatinibRelapsed or refractory PTCLCELTIC-1: a phase 2/3 study of cerdulatinib in patients with relapsed or refractory peripheral T-cell lymphoma2/3Not yet recruiting--NCT04021082--*BTK inhibitorIbrutinibSuppressing BTK enzymatic activity through a irreversible covalent bond with a cysteine residue in the BTK active site*IbrutinibRelapsed or refractory B-NHLsStudy of the safety and tolerability of ibrutinib in patients with recurrent B-cell lymphoma1/2Completed60%/16%NCT00849654^[@CR193]^IbrutinibRelapsed or refractory DLBCLSafety and efficacy study of a Bruton's tyrosine kinase inhibitor in subjects with relapsed or refractory diffuse large B-cell lymphoma1/2CompletedABC-DLBCL, 37%/16%; GCB-DLBCL, 5%/0%NCT01325701^[@CR194]^IbrutinibRelapsed or refractory FLIbrutinib in treating patients with relapsed or refractory follicular lymphoma2Active, not recruiting37.5%/12.5%NCT01849263^[@CR195]^IbrutinibRelapsed or refractory MZLStudy of the Bruton's tyrosine kinase inhibitor in subjects with relapsed or refractory marginal zone lymphoma2Completed48%/3%NCT01980628^[@CR196]^IbrutinibRelapsed or refractory MCLSafety and efficacy of ibrutinib in participants with relapsed or refractory mantle cell lymphoma2Completed68%/21%NCT01236391^[@CR197]^Ibrutinib, nivolumabRelapsed or refractory B-NHLs, CLL/SLLA study to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the combination of ibrutinib with nivolumab in participants with hematologic malignancies1/2Active, not recruitingDLBCL, 36%/16%; FL, 33%/10%; CLL/SLL, 61%/0%NCT02329847^[@CR198]^Ibrutinib, venetoclaxMCLVenetoclax plus ibrutinib in mantle cell lymphoma (AIM)2Completed71%/62%NCT02471391^[@CR199]^Ibrutinib, lenalidomide, rituximabUntreated and unfit elderly DLBCLStudy evaluating the safety and efficacy of ibrutinib, lenalidomide, and rituximab in untreated and unfit elderly patients with DLBCL2Recruiting--NCT03949062--Ibrutinib, lenalidomide, rituximabUntreated FLIbrutinib, lenalidomide, and rituximab in treating patients with previously untreated stage II--IV follicular lymphoma1Active, not recruiting95%/NANCT01829568^[@CR200]^Ibrutinib, lenalidomide, rituximabRelapsed or refractory MCLA trial of ibrutinib, lenalidomide, and rituximab for patients with relapsed or refractory mantle cell lymphoma (PHILEMON)2Recruiting76%/56%NCT02460276^[@CR201]^Ibrutinib, R-CHOPUntreated CD20^+^ B-NHLsA study combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients With CD20^+^ B-cell non-Hodgkin's lymphoma1Completed100%/NANCT01569750^[@CR202]^Ibrutinib, R-CHOP vs. placebo, R-CHOPUntreated non-GCB DLBCLA study of the Bruton's tyrosine kinase inhibitor, ibrutinib, in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with newly diagnosed non-germinal center B-cell subtype of diffuse large B-cell lymphoma3Active, not recruitingIbrutinib, R-CHOP, NA/67.3%; placebo, R-CHOP, NA/68.0%NCT01855750--Ibrutinib, high-dose methotrexate, rituximabRelapsed or refractory CNSLBruton's tyrosine kinase inhibitor, ibrutinib, in patients with relapsed or refractory primary central nervous system lymphoma and relapsed or refractory secondary central nervous system lymphoma1/2Active, not recruitingPhase 1 part: 80%/53%NCT02315326^[@CR203]^*AcalabrutinibA new, irreversible and second-generation BTK inhibitor with enhanced efficacy and improved off-target effect*AcalabrutinibRelapsed or refractory MCLAn open-label, phase 2 study of acalabrutinib in subjects with mantle cell lymphoma2Active, not recruiting81%/40%NCT02213926^[@CR205]^AcalabrutinibRelapsed CLLAcalabrutinib, a novel bruton tyrosine kinase inhibitor, for treatment of chronic lymphocytic leukemia1/2Active, not recruiting95%/0%NCT02029443^[@CR206]^Acalabrutinib vs. ibrutinibPreviously treated high-risk CLLStudy of acalabrutinib versus ibrutinib in previously treated subjects with high-risk CLL3Active, not recruiting--NCT02477696--Acalabrutinib, pembrolizumabHematologic malignanciesAcalabrutinib in combination with pembrolizumab, for treatment of hematologic malignancies (KEYNOTE145)1/2Active, not recruiting--NCT02362035--Acarabrutinib, venetoclaxRelapsed or refractory MCLAcalabrutinib and venetoclax in treating patients with relapsed or refractory mantle cell lymphoma2Recruiting--NCT03946878--Acalabrutinib, BR vs. placebo, BRUntreated MCLA study of bendamustine and rituximab alone versus in combination with acalabrutinib in subjects with previously untreated mantle cell lymphoma3Recruiting--NCT02972840--Acalabrutinib, R-CHOPUntreated DLBCLA combination of acalabrutinib with R-CHOP for patient with diffuse large B-cell lymphoma (ACCEPT)1/2Recruiting--NCT03571308--acalabrutinib, R-ICErelapsed or refractory DLBCLAcalabrutinib plus R-ICE for relapsed or refractory diffuse large B-cell lymphoma2Not yet recruiting--NCT03736616--*ZanubrutinibA second-generation BTK inhibitor showing distinguished kinase selectivity and lower side effect*ZanubrutinibB-cell lymphoid malignanciesStudy of the safety and pharmacokinetics of zanubrutinib in subjects with B-cell lymphoid malignancies1Active, not recruitingtotal, 96.2%/2.6%; treatment-naïve, 100%/4.5%; relapsed or refractory, 94.6%/1.8%NCT02343120^[@CR207]^ZanubrutinibRelapsed or refractory non-GCB DLBCLStudy of BTK inhibitor zanubrutinib in subjects with relapsed or refractory non-GCB type diffuse large B-cell lymphoma2Active, not recruiting--NCT03145064--ZanubrutinibRelapsed or refractory MZLStudy of zanubrutinib in patients with marginal zone lymphoma2Recruiting--NCT03846427--ZanubrutinibRelapsed or refractory MCLStudy to evaluate efficacy and safety of zanubrutinib in subjects with relapsed or refractory mantle cell lymphoma2Active, not recruiting--NCT03206970--Zanubrutinib vs. ibrutinibRelapsed or refractory CLLA study of zanubrutinib versus ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia (ALPINE)3Recruiting--NCT03734016--Zanubrutinib vs. ibrutinibWMA study comparing zanubrutinib and ibrutinib in subjects with Waldenström's macroglobulinemia3Active, not recruiting--NCT03053440--*TirabrutinibA highly selective irreversible BTK inhibitor*Tirabrutinibrelapsed or refractory NHLs/CLLPhase 1 study of tirabrutinib given as monotherapy in patients with relapsed or refractory NHLs and CLL1CompletedABC-DLBCL, 35%/9.7%; MCL, 92%/46%; CLL, 96%/NANCT01659255^[@CR208]^*M7583A novel irreversible BTK inhibitor*M7583B-cell malignanciesBTK inhibitor in B-cell malignancies1/2Active, not recruiting--NCT02825836--*VecarutinibA noncovalent or reversible BTK inhibitor*VecarutinibB-NHLsSafety and antitumor activity of vecabrutinib in B-lymphoid cancers1/2Recruiting--NCT03037645--*ARQ-531A reversible BTK inhibitor with off-target activity against Src and Tec family of protein tyrosine kinases*ARQ-531Hematologic malignanciesSafety and antitumor activity of ARQ-531 in hematologic malignancies1Recruiting--NCT03162536--*ICP-022A novel BTK inhibitor*ICP-022Relapsed or refractory B-cell malignanciesDose escalation of ICP-022 in patients with relapsed or refractory B-cell malignancies1Recruiting--NCT04014205--*LOXO-305A novel, selective noncovalent or reversible BTK inhibitor*LOXO-305CLL/SLL, NHLsA study of oral LOXO-305 in patients with previously treated CLL/SLL or NHLs1/2Recruiting--NCT03740529--NA: ORR or CR are not available on the clinicaltrials.gov or from the published article although the trial has been completed*R-CHOP* rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone, *BR* bendamustine and rituximab, *R-ICE* rituximab, ifosfamide, carboplatin, etoposide

BCR-BTK {#Sec21}
-------

The activation of BCR leads to the phosphorylation of LYN and SYK, which phosphorylate tyrosine residues in the cytoplasmic part of CD19 and B-cell adaptor for PI3K (BCAP), inducing PI3K activation, phosphatidylinositol 4,5-bisphosphate (PIP2) transformation to phosphatidylinositol 3,4,5-trisphosphate (PIP3), and BTK recruitment. BTK activation leads to PLCγ2 phosphorylation, which could further hydrolyze PIP2 to produce 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG).^[@CR185]^ IP3 is involved in intracellular calcium regulation and nuclear factor of activated T cells (NFAT) transcription, and DAG is associated with protein kinase Cβ (PKCβ) and mitogen-activated protein kinase (MAPK) family activation.^[@CR186]^ PKCβ also participates in the NF-κB pathway through a scaffold complex including CARD11, BCL-10, and MALT1. BTK plays a key role in the tonic BCR signaling pathway through the positive regulation of AKT phosphorylation (Fig. [1](#Fig1){ref-type="fig"}).^[@CR187]^ The inhibition of BTK decreased BTK^Y223^ phosphorylation and anti-apoptotic protein expression (BCL-2, BCL-XL, and MCL-1), resulting in increased apoptosis in MCL cell lines.^[@CR188]^ Moreover, recurrent gene mutations of the BCR-BTK signaling pathway are frequently found in ABC-DLBCL, FL, and marginal zone lymphoma (MZL).^[@CR4],[@CR189]--[@CR192]^

Ibrutinib is an irreversible BTK inhibitor that suppresses BTK enzymatic activity through a covalent bond with a cysteine residue in the BTK active site. A phase 1/2 study (NCT00849654) of ibrutinib enrolled patients with relapsed or refractory B-NHLs and reported promising safety and response (ORR 60% and CR 16%).^[@CR193]^ In a phase 1/2 trial (NCT01325701) of relapsed or refractory DLBCL, ibrutinib induced an ORR of 37% in ABC-DLBCL but only an ORR of 5% in GCB-DLBCL.^[@CR194]^ A phase 2 trial (NCT01849263) of ibrutinib in relapsed or refractory FL reported an ORR of 37.5% (CR 12.5%).^[@CR195]^ Ibrutinib has also been actively investigated in other relapsed or refractory B-NHLs and has shown clinical efficacy (NCT01980628 and NCT01236391).^[@CR196],[@CR197]^ A phase 1/2 trial (NCT02329847) of ibrutinib in combination with nivolumab in relapsed or refractory B-cell malignancies revealed an ORR of 36% in DLBCL (CR 16%), 33% in FL (CR 10%), and 61% in CLL/SLL (CR 0%).^[@CR198]^ Moreover, a phase 2 study (NCT02471391) of ibrutinib combined with venetoclax in MCL reported an ORR of 71% (CR 62%).^[@CR199]^ The combination of ibrutinib, lenalidomide, and rituximab is being explored in a phase 2 trial (NCT03949062) to evaluate its efficacy and safety in untreated and unfit elderly DLBCL patients. This combination also induced an ORR of 95% in untreated FL in a phase 1 trial (NCT01829568), as well as an ORR of 76% (CR 56%) in relapsed or refractory MCL in a phase 2 trial (NCT02460276).^[@CR200],[@CR201]^ In untreated CD20^+^ B-NHLs, ibrutinib plus R-CHOP achieved an ORR of 100% in a phase 1 study (NCT01569750).^[@CR202]^ In addition, in a phase 3 study (NCT01855750) in untreated non-GCB DLBCL, ibrutinib plus R-CHOP produced a CR rate of 67.3%, and placebo plus R-CHOP produced a CR rate of 68.0%, with no statistically significant difference. Moreover, the sequential combination of ibrutinib with high-dose methotrexate and rituximab was studied in patients with primary central nervous system lymphoma (PCNSL) (NCT02315326).^[@CR203]^

Acalabrutinib (ACP-196) is a BTK inhibitor that has been proven to have a more enhanced efficacy than ibrutinib in canine studies.^[@CR204]^ A phase 2 study (NCT02213926) reported an ORR of 81% (CR 40%) in relapsed or refractory MCL.^[@CR205]^ The FDA has approved acalabrutinib for treating relapsed or refractory MCL. Moreover, in a phase 1/2 trial (NCT02029443) of acalabrutinib in relapsed CLL, the ORR was 95%, and a 100% ORR was obtained among patients with chromosome 17p13.1 deletion.^[@CR206]^ A phase 3 trial (NCT02477696) of acalabrutinib vs ibrutinib in high-risk CLL is ongoing. Trials on acalabrutinib in combination with pembrolizumab (NCT02362035), venetoclax (NCT03946878), BR (NCT02972840), R-CHOP (NCT03571308), or R-ICE (NCT03736616) in hematological malignancies are ongoing. Zanubrutinib (BGB-3111) is a second-generation BTK inhibitor that has a promising ORR (96.2%) with low toxicity in CLL/SLL patients in a phase 1 trial (NCT02343120).^[@CR207]^ Phase 2 trials of zanubrutinib in relapsed or refractory DLBCL (NCT03145064), MZL (NCT03846427), and MCL (NCT03206970), as well as phase 3 trials (NCT03734016 and NCT03053440) comparing zanubrutinib with ibrutinib in patients with relapsed or refractory CLL or WM, are ongoing. Tirabrutinib (ONO/GS-4059), a highly selective irreversible BTK inhibitor, achieved a response of 35%, 92%, and 96% in relapsed or refractory ABC-DLBCL, MCL, and CLL patients, respectively, in a phase 1 trial (NCT01659255).^[@CR208]^ M7583, a novel irreversible BTK inhibitor, is being explored in a phase 1/2 trial (NCT02825836) in patients with relapsed or refractory B-cell malignancies. Vecabrutinib (SNS-062), a noncovalent or reversible BTK inhibitor, suppresses both wild-type and C481S-mutated BTK activity and is being investigated in a phase 1/2 trial (NCT03037645) in B-NHLs. ARQ-531 is another reversible BTK inhibitor with off-target activity against the Src and Tec family of protein tyrosine kinases. Compared with ibrutinib, ARQ-531 has a better capacity to reduce CLL cell viability in mice.^[@CR209]^ In addition, a phase 1 trial (NCT03162536) of ARQ-531 in patients with hematological malignancies is ongoing. Trials on ICP-022 and LOXO-305, which are also novel BTK inhibitors, are recruiting patients with refractory B-cell malignancies (NCT04014205 and NCT03740529).

PI3K-AKT-mTOR {#Sec22}
-------------

The PI3K-AKT-mTOR pathway is an important regulator in normal myeloid and lymphoid development.^[@CR210]^ Upon activation, BCAP is upregulated, and the catalytic subunit of PI3K (referred to as p110α, p110β, p110γ, and p110δ for the four different isoforms) triggers PIP3 and recruits the serine/threonine kinase AKT to the plasma membrane.^[@CR211]^ AKT can subsequently activate mTOR, which encompasses two different multiprotein complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). mTORC1 phosphorylates 4E-BP1 and S6K1 to activate key drivers of protein translation (Fig. [1](#Fig1){ref-type="fig"}).^[@CR212]^ Downstream signaling of BCR is largely dependent on p110δ, and mutations in *PIK3CA* (the gene encoding p110α) were found in approximately 1--8% of DLBCL.^[@CR213],[@CR214]^ In T-NHLs, p110δ and p110γ are vital kinases of TCR signaling and chemokine receptor signaling, respectively.^[@CR215]--[@CR217]^

The targeted drugs and clinical trials related to the PI3K-AKT-mTOR, JAK-STAT, NOTCH, and NF-κB signaling pathways are listed in Table [3](#Tab3){ref-type="table"}. Idelalisib (CAL-101, GS-1101), a p110δ-selective inhibitor, is the first FDA-approved PI3K inhibitor in treating relapsed FL and SLL. A phase 2 trial (NCT01393106) demonstrated that idelalisib was tolerable and had modest single-agent activity in relapsed or refractory HL (ORR 68% and CR 4%).^[@CR218]^ Another phase 2 trial (NCT01282424) of idelalisib treated indolent NHLs including FL, SLL, MZL, and lymphoplasmacytic lymphoma (LPL) with or without WM and showed antitumor activity with an acceptable safety profile (ORR 57% and CR 6%).^[@CR219]^ Moreover, combinations of idelalisib with other novel agents may improve the response rate and DoR. Studies of idelalisib in combination with obinutuzumab in relapsed or refractory FL (NCT03890289) and in combination with BR in indolent B-NHLs and MCL (NCT01088048 and NCT01090414) are ongoing. However, two phase 1 trials of idelalisib and lenalidomide in patients with recurrent FL (NCT01644799) and MCL (NCT01838434) showed emerging toxicities as new combinations.^[@CR220]^ Umbralisib (TGR-1202) and parsaclisib (INCB050465) are also p110δ inhibitors with different chemical structures.^[@CR221]^ A phase 1 trial (NCT02268851) of umbralisib and ibrutinib showed an ORR of 67% (CR 19%) in relapsed or refractory MCL.^[@CR222]^ Duvelisib (IPI-145/INK1197), which is an inhibitor of both p110δ and p110γ, showed efficacy in various types of lymphomas, including DLBCL and MCL, in preclinical studies.^[@CR223],[@CR224]^ A phase 2 trial (NCT01882803) of duvelisib monotherapy in relapsed or refractory indolent NHLs demonstrated an ORR of 46% (41% in FL, 33% in MZL, and 68% in SLL).^[@CR225]^Table 3Targeted drugs and clinical trials related to the PI3K-AKT-mTOR, JAK-STAT, NOTCH, and NF-κB signaling pathwaysDrugDiseaseTrial namePhaseStatusORR/CRNCT\#Reference*PI3k-AKT-mTOR pathwayIdelalisibA p110δ-selective inhibitor*IdelalisibRelapsed or refractory HLSafety and efficacy of idelalisib in relapsed or refractory Hodgkin's lymphoma2Completed68%/4%NCT01393106^[@CR218]^IdelalisibIdolent B-NHLsEfficacy and safety study of idelalisib in subjects with indolent B-cell non-Hodgkin's lymphoma (DELTA)2Completed57%/6%NCT01282424^[@CR219]^Idelalisib, obinutuzumabRelapsed or refractory FLIdelalisib plus obinutuzumab in patients with relapsed or refractory follicular lymphoma (GAUDEALIS)2Not yet recruiting--NCT03890289--Idelalisib, BRRelapsed or refractory indolent B-NHLs/MCL/CLLStudy to investigate idelalisib in combination with chemotherapeutic agents, immunomodulatory agents and anti-CD20 monoclonal antibody in subjects with relapsed or refractory indolent B-cell non-Hodgkin's lymphoma, mantle cell lymphoma or chronic lymphocytic leukemia1Completed81%/32%NCT01088048, NCT01090414--Idelalisib, lenalidomideRecurrent FLLenalidomide and idelalisib in treating patients with recurrent follicular lymphoma1CompletedNANCT01644799^[@CR220]^Idelalisib, lenalidomideRelapsed or refractory MCLLenalidomide with or without idelalisib in treating patients with relapsed or refractory mantle cell lymphoma1CompletedNANCT01838434^[@CR220]^*UmbralisibA second-generation p110δ-selective inhibitor*Umbralisib, ibrutinibCLL/MCLA phase 1 safety and efficacy study of the PI3K-delta Inhibitor umbralisib and ibrutinib in patients with CLL or MCL1CompletedMCL, 67%/19%; CLL, 90%/29%NCT02268851^[@CR222]^*DuvelisibA PI3Kδ/γ inhibitor*DuvelisibRefractory iNHLsA phase 2 study of duvelisib in subjects with refractory indolent non-Hodgkin's lymphoma (DYNAMO)2Active, not recruiting46%/NANCT01882803^[@CR225]^*TemsirolimusA mTOR inhibitor*TemsirolimusMCLStudy evaluating temsirolimus in mantle cell lymphoma (OPTIMAL)3Completed38%/3%NCT00117598^[@CR226]^Temsirolimus vs. ibrutinibRelapsed or refractory MCLStudy of ibrutinib versus temsirolimus in patients with relapsed or refractory mantle cell lymphoma who have received at least one prior therapy3CompletedNANCT01646021^[@CR227]^Temsirolimus, rituximab, DHAPRelapsed or refractory DLBCLTemsirolimus, rituximab, and DHAP for relapsed or refractory diffuse large B-cell lymphoma (STORM)2Unknown--NCT01653067^[@CR228]^*EverolimusAn oral mTOR inhibitor*Everolimus, itacitinibHLEverolimus plus itacitinib in Hodgkin's lymphoma1/2Recruiting--NCT03697408--Everolimus, panobinostatRelapsed or refractory lymphomaEverolimus plus panobinostat in patients with relapsed or refractory lymphoma1/2CompletedNANCT00967044--*JAK-STAT pathwayRuxolitinibA JAK1/2 inhibitor*RuxolitinibRelapsed or refractory cHLA phase 2 study of oral JAK1/JAK2 inhibitor ruxolitinib in adult patients with relapsed or refractory classical Hodgkin's lymphoma (HIJAK)2Completed9.4%/0%NCT01877005^[@CR245]^Ruxolitinib, nivolumabRelapsed or refractory cHLNivolumab with ruxolitinib in relapsed or refractory classical Hodgkin's lymphoma1Recruiting--NCT03681561--*ItacitinibA JAK1 selective inhibitor*Itacitinib, everolimusHLItacitinib plus everolimus in Hodgkin's lymphoma1/2Recruiting--NCT03697408--Itacitinib, ibrutinibRelapsed or refractory DLBCLA study of itacitinib in combination with ibrutinib in subjects with relapsed or refractory diffuse large B-cell lymphoma1/2Active, not recruiting--NCT02760485--*NOTCH signaling pathwayBMS-906024A γ-secretase inhibitor*BMS-906024, dexamethasoneT-ALL/T-LBLStudy to evaluate the safety and tolerability of weekly intravenous doses of BMS-906024 in subjects with acute T-cell lymphoblastic leukemia or T-cell lymphoblastic lymphoma1CompletedNANCT01363817--*LY3039478A γ-secretase inhibitor*LY3039478, dexamethasoneT-ALL/T-LBLA study of LY3039478 in combination with dexamethasone in participants with acute T-cell lymphoblastic leukemia or T-cell lymphoblastic lymphoma1/2Completed--NCT02518113--*CB-103A pan-NOTCH inhibitor*CB-103Solid tumors/NHLsStudy of CB-103 in adult patients with advanced or metastatic solid tumors and hematological malignancies1/2Recruiting--NCT03422679--*NF-κB pathwayPevonedistatA NEDD8-activating enzyme inhibitor*Pevonedistat, ibrutinibRelapsed or refractory CLL/NHLPevonedistat and ibrutinib in treating participants with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin's lymphoma1Recruiting--NCT03479268--*SNX-5422A synthetic, novel, small-molecule HSP90 Inhibitor*SNX-5422Solid tumors/lymphomasSafety study of SNX-5422 to treat solid tumor cancers and lymphomas1CompletedNANCT00647764--SNX-5422Solid tumors/lymphomasSNX-5422 to treat solid tumor cancers and lymphoma1CompletedNANCT00644072--NA: ORR or CR are not available on the clinicaltrials.gov or from the published article, although the trial has been completed*DHAP* dexamethasone, high-dose cytarabine, cisplatin, *T-ALL* acute T-cell lymphoblastic leukemia

Temsirolimus (CCI-779) is a derivative of rapamycin, and a phase 2 trial (NCT00117598) of temsirolimus as a single agent in relapsed MCL showed an ORR of 38% (CR 3%).^[@CR226]^ In a randomized phase 3 trial (NCT01646021) enrolling patients with relapsed or refractory MCL, significant improvement in PFS and better tolerance were observed in patients treated with ibrutinib vs temsirolimus.^[@CR227]^ Another ongoing study (NCT01653067) is evaluating temsirolimus in combination with DHAP in patients with relapsed or refractory DLBCL.^[@CR228]^ Everolimus (RAD001) is an oral mTOR inhibitor that has been used as a single agent in relapsed or refractory aggressive and indolent NHLs as well as HL.^[@CR229]--[@CR231]^ Clinical trials (NCT03697408 and NCT00967044) to assess everolimus combined with other agents, such as itacitinib and panobinostat, are recruiting patients.

JAK-STAT {#Sec23}
--------

The JAK-STAT pathway is activated by extracellular cytokines such as interferons, IL-2, IL-6 and growth factors, which regulate cell survival, proliferation, differentiation, and apoptosis.^[@CR232],[@CR233]^ There are four cytoplasmic JAK kinases: JAK1, JAK2, JAK3, and TYK2. JAK1/JAK3 are prone to immunoregulation, while JAK2 is associated with erythrocyte and platelet formation.^[@CR234],[@CR235]^ JAKs lead to STAT phosphorylation, homodimerization, and nuclear translocation (Fig. [1](#Fig1){ref-type="fig"}).^[@CR233],[@CR236]^ There are seven STAT proteins (STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and STAT6).^[@CR234],[@CR235]^ The activation of the JAK/STAT signaling pathway, as assessed by STAT3 or STAT5B phosphorylation, was present in T-NHLs, including anaplastic lymphoma kinase (ALK)-positive and ALK-negative ALCL,^[@CR237],[@CR238]^ HTLV-1-associated ATLL,^[@CR239],[@CR240]^ and NKTCL.^[@CR241],[@CR242]^ Twenty percent of ALK-negative ALCL patients present mutations of the JAK1 and/or STAT3 genes,^[@CR237]^ and approximately 10% of NKTCL patients present STAT3 mutations.^[@CR243]^

Ruxolitinib (INCB018424) is a JAK1/2 inhibitor approved by the FDA to treat myelofibrosis. Ruxolitinib significantly enhanced apoptosis in HL and PMBCL in vitro and promoted survival in a lymphoma xenograft murine model.^[@CR244]^ A phase 2 study (NCT01877005) of ruxolitinib in advanced relapsed or refractory HL showed poor efficacy as monotherapy (ORR 9.4% and CR 0%).^[@CR245]^ Ruxolitinib and navitoclax, a Bcl-2/Bcl-XL inhibitor, reduced the tumor burden and prolonged survival in an ATLL xenograft murine model.^[@CR246]^ A phase 1 study (NCT03681561) of ruxolitinib in combination with nivolumab in relapsed or refractory HL is currently recruiting patients. However, ruxolitinib has off-target effects due to JAK2 inhibition, which may lead to thrombocytopenia, anemia, and neutropenia.^[@CR247]^ Therefore, agents that can selectively inhibit JAK1, such as itacitinib (INCB039110), are expected to better treat lymphomas in view of the risk-benefit ratio. A phase 1/2 study (NCT03697408) of itacitinib in combination with everolimus in relapsed or refractory HL is ongoing. In addition, a phase 1/2 trial (NCT02760485) of itacitinib in combination with ibrutinib in subjects with relapsed or refractory DLBCL is also active.

NOTCH {#Sec24}
-----

NOTCH receptors are single-pass type I transmembrane proteins. Four receptors (NOTCH1-4) are expressed in mammals and share a common structure. Among them, NOTCH1 and NOTCH2 are the most widely expressed receptors and play a role in cell growth, proliferation, survival, and differentiation.^[@CR248]^ NOTCH is cleaved in the transmembrane region by the γ-secretase complex, which can be inhibited by small-molecule γ-secretase inhibitors (GSIs). After release from the membrane, the intracellular portion of the NOTCH receptor translocates to the nucleus, where it interacts with the RBPJ DNA-binding protein and recruits the MAML1 transcriptional coactivator to assemble the transcriptional complex and start transcription. The signal can be terminated by the proteasome (Fig. [1](#Fig1){ref-type="fig"}).^[@CR249]^ Mutations of NOTCH1 and NOTCH2 have been reported to mediate the differentiation of B- or T-cell lineages.^[@CR250]^ In T-cell lymphoblastic lymphoma (T-LBL), *NOTCH1* mutations vary from 30% to 80%.^[@CR251]^ In DLBCL, *NOTCH1* mutations are classified into the N1 subtype, which accounts for 6.1% of ABC DLBCL cases and is associated with poor prognosis.^[@CR252]^ Activation of the NOTCH1 pathway was also observed in MCL, HL and BL.^[@CR253]--[@CR255]^ *NOTCH2* mutations are present in approximately 25% of patients with splenic marginal zone lymphoma (SMZL) and approximately 5% of patients with non-splenic MZL^[@CR253]^ and are related to adverse clinical outcomes.^[@CR253],[@CR256],[@CR257]^ In addition, a similar gene profile has been found in FL.^[@CR258]^ In DLBCL, the BN2 subtype is characterized by *BCL6* fusions and *NOTCH2* mutations and presents a relatively good prognosis.^[@CR252]^

For targeted agents of the NOTCH pathway, GSIs, as well as antibodies against NOTCH, Delta/Jagged ligands, or other extracellular components involved in the NOTCH signaling cascade, have been tested in multiple clinical trials.^[@CR259]^ GSIs can suppress the release of ICN1 from the membrane and effectively abrogate the activation of NOTCH1 transcriptional programs in cell lines.^[@CR260]^ A phase 1 trial (NCT01363817) evaluating the safety and tolerability of BMS-906024 in subjects with T-LBL was completed. Another study showed strong synergy between glucocorticoids and GSIs.^[@CR261]^ A phase 1/2 trial (NCT02518113) to evaluate LY3039478 in combination with dexamethasone in T-LBL patients was also completed. However, GSIs demonstrated dose-limiting goblet cell hyperplasia of the gut, mainly due to the inhibition of both NOTCH1 and NOTCH2 expression on these tissues.^[@CR262]^ In addition, a phase 1/2 trial (NCT03422679) to investigate the safety, tolerability, and preliminary efficacy of CB-103, a pan-NOTCH inhibitor, is recruiting patients. More research and clinical trials are needed to better understand targeted therapy of the NOTCH pathway.

NF-κB {#Sec25}
-----

The NF-κB pathway is one of the key signaling pathways implicated in physiological cellular functions and neoplastic processes.^[@CR263],[@CR264]^ Core components of the NF-κB pathway are inhibitors of NF-κB (IκB) proteins, the IκB kinase (IKK) complex, and NF-κB transcription factors, which include RelA/p65, RelB, c-Rel/Rel, p50, and p52.^[@CR265]^ B-cell associated kinases (BAKs), such as BTK or PI3Kδ, are critical signaling transducers of BCR signaling and can trigger a cascade reaction to form a multiprotein CARD11-BCL-10-MALT1 (CBM) complex.^[@CR266]^ This complex interacts with IKK, the upstream molecule of NF-κB, and promotes NF-κB activation (Fig. [1](#Fig1){ref-type="fig"}).^[@CR267]--[@CR270]^ The constitutive activation of NF-κB is common in most types of B-NHLs.^[@CR269]^ In DLBCL, NF-κB activity is upregulated in PMBCL and ABC-DLBCL but not in GCB-DLBCL.^[@CR173]^ BCR-dependent NF-κB activation was the highest in the MCD subtype (based on the cooccurrence of MYD88 L265P and CD79B mutations) and BN2 subtype.^[@CR252]^ In CLL, the NF-κB pathway is usually activated through BCR and TLRs.^[@CR271]^ For mucosa-associated lymphoid tissue (MALT) lymphomas, intrinsic BCR activation is associated with an advanced stage.

The NF-κB pathway can be inhibited by directly or indirectly targeting NF-κB components. As a direct targeting agent, pevonedistat (TAK-924/MLN4924), a NEDD8-activating enzyme (NAE) inhibitor, suppresses NF-κB activity by blocking phospho-IκBα degradation.^[@CR272]^ A phase 1 study (NCT03479268) of relapsed or refractory CLL and NHLs is ongoing. HSP90 is a component of the IKK complex and prevents the proteasomal degradation of IKKα and IKKβ.^[@CR270]^ Two phase 1 trials (NCT00647764 and NCT00644072) of the HSP90 inhibitor SNX-5422 in patients with lymphomas were completed.

Proteasome {#Sec26}
----------

UPP is a choreographed system that degrades misfolded proteins in all eukaryotic cells. It plays a role in the processes of cell apoptosis, cell-cycle progression, antigen presentation, and DNA repair.^[@CR273]--[@CR276]^ The first step of protein degradation is polyubiquitination, and the proteasome binds the polyubiquitin chain and mediates deubiquitination and then degrades the target proteins to oligopeptides less than 25 amino acids (Fig. [1](#Fig1){ref-type="fig"}).^[@CR277],[@CR278]^ Inhibition of the pro-survival NF-κB pathway is the main antitumor mechanism of proteasome inhibitors in lymphoma.^[@CR279]^

The targeted drugs and clinical trials related to the proteasome are listed in Table [4](#Tab4){ref-type="table"}. Currently, three proteasome inhibitors (bortezomib, carfilzomib, and ixazomib) are approved for MM or MCL. Bortezomib, a reversible proteasome inhibitor, binds primarily with β5 and, to a lesser extent, with β2 and β1 of the 20S proteasome particle.^[@CR280]^ A phase 2 trial (NCT00063713) of bortezomib in relapsed or refractory MCL reported an ORR of 31% (CR 8%).^[@CR281]^ Another phase 2 trial (NCT00901147) of bortezomib and panobinostat showed an ORR of 43% (CR 22%) in relapsed or refractory PTCL patients.^[@CR282]^ Bortezomib in combination with other agents, such as ibrutinib in MCL (NCT02356458), dexamethasone in CTCL (NCT03487133), and chemotherapeutic regimens, such as gemcitabine, dexamethasone, and cisplatin (GDP) in DLBCL (NCT02542111) and CHOP in T-NHLs (NCT00374699), are currently ongoing. A randomized phase 3 trial (NCT00722137) compared the efficacy of R-CHOP with bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) in untreated MCL, showing an improved median PFS but increased hematologic toxicity.^[@CR283]^ Moreover, a phase 2 trial of bortezomib, low-dose dexamethasone, and rituximab (NCT00981708) presented an ORR of 85% (CR 3%) in untreated WM.^[@CR284]^ A phase 3 trial (NCT01788020) conducted in WM patients to evaluate bortezomib in combination with dexamethasone, cyclophosphamide, and rituximab is ongoing. Other proteasome inhibitors, including the irreversible carfilzomib and the reversible oral inhibitor ixazomib, have been studied in a variety of clinical trials. Trials of carfilzomib (NCT01336920) alone or in combination with other agents including vorinostat (NCT01276717), romidepsin (NCT03141203), umbralisib (NCT02867618), rituximab (NCT03269552), BR (NCT02187133), R-CHOP (NCT02073097) and R-ICE (NCT01959698) in relapsed or refractory lymphoma are ongoing. Phase 2 trials of ixazomib showed an ORR of 8.3% (CR 0%) in relapsed or refractory FL (NCT01939899) and an ORR of 67% in relapsed or refractory CTCL/PTCL (NCT02158975). Ixazomib in combination with rituximab (NCT02339922) or with ibrutinib (NCT03323151) is currently under evaluation in indolent B-NHLs and MCL. Phase 1/2 trials of ixazomib combined with romidepsin (NCT03547700) in refractory PTCL and with rituximab and lenalidomide as frontline therapy in high-risk indolent B-NHLs (NCT02898259) are ongoing.Table 4Targeted drugs and clinical trials related to the proteasomeDrugDiseaseTrial namePhaseStatusORR/CRNCT\#Reference*Proteasome inhibitorBortezomibA reversible proteasome inhibitor binding primarily with β5 and to a lesser extent, with β2 and β1 of the 20S proteasome particle*BortezomibRelapsed or refractory MCLBortezomib in subjects with relapsed or refractory mantle cell lymphoma2Completed31%/8%NCT00063713^[@CR281]^Bortezomib, panobinostatRelapsed or refractory PTCLStudy of bortezomib and panobinostat in treating patients with relapsed or refractory peripheral T-cell lymphoma2Completed43%/22%NCT00901147^[@CR282]^Bortezomib, ibrutinibMCLCombination of ibrutinib and bortezomib to treat patients with mantle cell lymphoma1/2Recruiting--NCT02356458--Bortezomib, dexamethasoneRelapsed or refractory CTCLBortezomib plus dexamethasone therapy in patients with relapsed or refractory cutaneous T-cell lymphoma2Recruiting--NCT03487133--Bortezomib, GDPNon-GCB DLBCLA study of bortezomib plus GDP in the treatment of relapsed or refractory non-GCB DLBCL2Unknown--NCT02542111--Bortezomib, CHOPAdvanced aggressive T-NHLs/NKTCLBortezomib and CHOP in patients with advanced-stage aggressive T-cell or NK/T-cell lymphoma1/2CompletedNANCT00374699--VR-CAP vs. R-CHOPUntreated MCLStudy of the combination of rituximab, cyclophosphamide, doxorubicin, bortezomib, and prednisone or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with newly diagnosed mantle cell lymphoma3CompletedNANCT00722137^[@CR283]^Bortezomib, dexamethasone, rituximabUntreated WMBortezomib, low-dose dexamethasone, and rituximab in untreated Waldenström's macroglobulinemia2Completed85%/3%NCT00981708^[@CR284]^Bortezomib, dexamethasone, rituximab, and cyclophosphamideWMEfficacy of First-Line Dexamethasone, Rituximab, and Cyclophosphamide +/− Bortezomib for Patients With Waldenström's Macroglobulinemia3Active, not recruiting--NCT01788020--*CarfilzomibA second-generation irreversible proteasome inhibitor binding to the β5 subunit of the 20S proteasome particle*CarfilzomibRelapsed or refractory T-NHLsCarfilzomib in treating patients with relapsed or refractory T-cell lymphoma1CompletedNANCT01336920--Carfilzomib, vorinostatRelapsed or refractory lymphomaStudy of carfilzomib and vorinostat for relapsed or refractory lymphoma1CompletedNANCT01276717--Carfilzomib, romidepsinRelapsed or refractory PTCLEvaluation of the combination of romidepsin and carfilzomib in relapsed or refractory peripheral T-cell lymphoma patients1/2Recruiting--NCT03141203--Carfilzomib, umbralisibRelapsed or refractory lymphomaCarfilzomib and umbralisib in treatment of relapsed or refractory lymphoma1/2Recruiting--NCT02867618--Carfilzomib, rituximabWM/MZLCarfilzomib with or without rituximab in the treatment of Waldenström's macroglobulinemia or marginal zone lymphoma2CompletedNANCT03269552--Carfilzomib, bendamustine, rituximabRelapsed or refractory NHLsCarfilzomib with bendamustine and rituximab in patients with relapsed or refractory non-Hodgkin's lymphoma1Recruiting--NCT02187133--Carfilzomib, R-CHOPDLBCLCarfilzomib, rituximab, and combination chemotherapy in treating patients with diffuse large B-cell lymphoma1/2Recruiting--NCT02073097--Carfilzomib, R-ICERelapsed or refractory DLBCLCarfilzomib, rituximab, ifosfamide, carboplatin, and etoposide in treating patients with relapsed or refractory stage I-IV diffuse large B-cell lymphoma1/2Recruiting--NCT01959698--*IxazomibA reversible proteasome inhibitor binding to the β5 subunit of the 20S proteasome particle*IxazomibRelapsed or refractory FLPhase 2 study of oral ixazomib in adult patients with relapsed or refractory follicular lymphoma2CompletedPSMB1 positice, 8.3%/0%; PSMB1 negative, 0%/0%NCT01939899--IxazomibRelapsed or refractory CTCL/PTCLOpen-label, phase 2 study of ixazomib in patients with relapsed or refractory cutaneous and peripheral T-cell lymphoma2Completed67%/NANCT02158975--Ixazomib, rituximabIndolent B-NHLsIxazomib and rituximab in treating patients with indolent B-cell non-Hodgkin's lymphoma2Recruiting--NCT02339922--Ixazomib, ibrutinibRelapsed or refractory MCLA study of ixazomib and ibrutinib in relapsed or refractory mantle cell lymphoma1/2Recruiting--NCT03323151--Ixazomib, romidepsinRelapsed or refractory PTCLStudy of ixazomib and romidepsin in peripheral T-cell lymphoma1/2Recruiting--NCT03547700--lenalidomide, ixazomib, rituximabHigh-risk indolent B-NHLsLenalidomide, ixazomib, and rituximab as frontline therapy for high-risk indolent B-cell lymphoma1/2Active, not recruiting--NCT02898259--NA: ORR or CR are not available on the clinicaltrials.gov or from the published article, although the trial has been completed*GDP* gemcitabine, dexamethasone, and cisplatin, *CHOP* cyclophosphamide, doxorubicin, vincristine, prednisolone, *VR-CAP* bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone, *R-CHOP* rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone, *R-ICE* rituximab, ifosfamide, carboplatin, etoposide, *PSMB1* proteasome subunit beta type-1

Directly targeting signaling pathways and off-target effects remain a major issue of signaling pathway inhibitors. For example, AEs of ibrutinib, such as atrial fibrillation and bleeding-related events, were connected with the irreversible targeting of ibrutinib on BTK signaling in cardiac myocytes and platelets.^[@CR285],[@CR286]^ The off-target inhibition of kinases containing an analogous cysteine residue with BTK^C481^ may also be crucial to the side effects of ibrutinib.^[@CR287]^ Moreover, drug resistance reduces the clinical efficacy, warranting further investigation on combined treatment and dual inhibitors. BTK^C481S^ in the ibrutinib binding site is associated with ibrutinib resistance^[@CR288],[@CR289]^ but can be overcome in combination with venetoclax.^[@CR290]^ mTOR inhibitors show limited long-term effectiveness due to feedback PI3K/AKT activation, while dual PI3K/mTOR inhibitors could be better alternatives.

Epigenetic regulation and targeted therapy {#Sec27}
==========================================

Epigenetic regulation mainly includes DNA methylation, histone acetylation and methylation. Histone acetylation and methylation regulate the chromatin state. In the active status, chromatin is accessible to transcription factors, which is represented by the enrichment of H3K27 acetylation and H3K4 methylation. In the repressive status, chromatin is compact and inaccessible to transcription factors, which is characterized by the enrichment of H3K36, H3K27 and H3K9 trimethylation (Fig. [2](#Fig2){ref-type="fig"}).^[@CR291]^ Epigenetic dysregulation plays an important role in both B- and T-NHLs and represents potential therapeutic targets according to preclinical data and clinical trials.Fig. 2Epigenetic modifications in lymphoma cells

DNA methylation and targeted therapy {#Sec28}
------------------------------------

### DNMT {#Sec29}

The main type of DNA methylation observed in mammals is the methylation of CpG dinucleotides.^[@CR292]^ DNA methyltransferases (DNMTs) mediate this process and induce transcriptional repression. DNMT1 maintains DNA methylation on hemimethylated CpG sites, whereas DNMT3A and DNMT3B are involved in DNA methylation on unmethylated CpG sites. In vitro, the molecular silencing of DNMT1 decreased the expression of cell-cycle genes, such as *CDK1*, *CCNA2*, and *E2F2*, in GCB-DLBCL-derived cell lines.^[@CR293]^ Analysis of DLBCL patients reported the overexpression of DNMT1, DNMT3A, and DNMT3B in 48%, 13%, and 45% of patients, respectively.^[@CR294]^ Moreover, *DNMT1* loss induced altered methylation levels and impaired tumor cell proliferation in mice with T-NHLs.^[@CR295]^ Almost all T-NHL subtypes harbor mutations of *DNMT3A*.^[@CR296]^

The targeted drugs and clinical trials related to epigenetic modifications are listed in Table [5](#Tab5){ref-type="table"}. Azacitidine, a demethylating agent, inhibits DNMTs by incorporating into RNA and DNA through covalent bonding to DNMTs. A phase 1/2 trial (NCT01120834) showed that azacitidine in combination with vorinostat induced an ORR of 6.7% in patients with relapsed or refractory DLBCL. Azacitidine was also studied in combination with R-CHOP in a phase 1/2 trial (NCT01004991) that reported a CR rate of 91.7% in 12 untreated DLBCL patients. In addition, there are some other trials investigating azacitidine plus R-ICE (NCT03450343) or rituximab and GDP (R-GDP) (NCT03719989) in relapsed or refractory DLBCL and azacitidine with CHOP (NCT03542266) in untreated PTCL patients. Decitabine, a DNMT inhibitor, inhibits DNMTs by incorporating into DNA and reversing DNA methylation and transcriptional repression. A phase 1 trial of low-dose decitabine in NHL and CLL reported dose-limiting myelosuppression.^[@CR297]^ Decitabine combined with R-CHOP is being studied in a phase 1/2 trial (NCT02951728) of untreated DLBCL patients with International Prognostic Index (IPI) \>1. Moreover, there is a recruiting phase 4 trial (NCT03579082) exploring the efficacy and safety of decitabine, rituximab, with/without DHAP in relapsed or refractory DLBCL. A phase 3 randomized trial (NCT03553537) is comparing the efficacy and safety of decitabine plus CHOP (D-CHOP) vs CHOP alone in patients with untreated PTCL.Table 5Targeted drugs and clinical trials related to epigenetic modificationsDrugDiseaseTrial namePhaseStatusORR/CRNCT\#Reference*DNMT inhibitorAzacitidineA DNMT inhibitor which is incorporated into RNA and, to a lesser extent, into DNA, and inhibits DNMTs*Azacitidine, vorinostatRelapsed or refractory DLBCLStudy of azacitidine in combination with vorinostat in patients with relapsed or refractory diffuse large B-cell lymphoma1/2Completed6.7%/NANCT01120834--Azacitidine, R-CHOPUntreated DLBCLPhase 1/2 trial of R-CHOP plus azacytidine in diffuse large B-cell lymphoma1/2CompletedNA/91.7%NCT01004991--Azacitidine, R-ICERelapsed or refractory DLBCLOral azacitidine plus salvage chemotherapy in relapsed or refractory diffuse large B-cell lymphoma1Recruiting--NCT03450343--Azacitidine, R-GDPRelapsed or refractory DLBCLAzacitidine and R-GDP in patients with relapsed or refractory diffuse large B-cell lymphoma (EPIC)2Not yet recruiting--NCT03719989--Azacitidine, CHOPUntreated PTCLAzacitidine plus CHOP in patients with untreated peripheral T-cell lymphoma2Recruiting--NCT03542266--*DecitabineA DNMT inhibitor which is incorporated into DNA and inhibits DNMTs through disrupting the interaction between DNA and DNMTs*Decitabine, R-CHOPUntreated DLBCL with IPI \> 1Decitabine plus R-CHOP in diffuse large B-cell lymphoma1/2Active, not recruiting--NCT02951728--Decitabine combined with R±DHAPRelapsed or refractory DLBCLA clinical trial of decitabine in relapse or refractory diffuse large B-cell lymphoma4Recruiting--NCT03579082--Decitabine plus CHOP vs. CHOPUntreated PTCLEfficacy and safety of decitabine plus CHOP vs. CHOP in patients with untreated peripheral T-cell lymphoma3Not yet recruiting--NCT03553537--*IDH2 inhibitorEnasidenibAn IDH2 inhibitor*EnasidenibAITLStudy of orally administered enasidenib in subjects with advanced solid tumors, including glioma, and with angioimmunoblastic T-cell lymphoma, with an *IDH2* mutation1/2CompletedNANCT02273739--*EZH2 inhibitorTazemetostatA selective inhibitor of EZH2*TazemetostatRelapsed or refractory B-NHLsOpen-label, multicenter, phase 1/2 study of tazemetostat as a single agent in subjects with advanced solid tumors or with B-cell lymphomas and tazemetostat in combination with prednisolone in subjects with DLBCL1/2Active, not recruitingPhase 1 part, 38%/14%NCT01897571^[@CR324]^*SHR2554A novel EZH2 inhibitor*SHR2554Relapsed or refractory mature lymphoid neoplasmsA phase 1 study of SHR2554 in subjects with relapsed or refractory mature lymphoid neoplasms1Recruiting--NCT03603951--*PF-06821497A novel EZH2 inhibitor*PF-06821497Relapsed or refractory FLPF-06821497 treatment of relapsed or refractory small cell lung cancer, castration resistant prostate cancer, and follicular lymphoma1Recruiting--NCT03460977--*HDAC inhibitorVorinostatA pan-HDAC inhibitor*VorinostatRelapsed or refractory DLBCLAn investigational drug study with vorinostat in relapsed diffuse large B-cell lymphoma (0683-013)2Completed5.6%/5.6%NCT00097929^[@CR334]^VorinostatRelapsed or refractory FL/other subtypes of indolent B-NHLs/MCLVorinostat in treating patients with low-grade non-Hodgkin's lymphoma2CompletedFL, 47%/23.5%; MZL, 22%/11%; MCL, 0%/0%NCT00253630^[@CR335]^VorinostatRelapsed and refractory CTCLOral vorinostat in advanced cutaneous T-cell lymphoma (0683-001)2Completed29.7%/0%NCT00091559^[@CR336]^Vorinostat, rituximabNHLsVorinostat and rituximab in treating patients with indolent non-Hodgkin's lymphoma2CompletedFL, 50%/40.9%; MZL, 50%/50%; MCL, 33.3%/0%; LPL, 0%/0%NCT00720876^[@CR337]^Vorinostat, R-CHOPNewly diagnosed advanced-stage DLBCLVorinostat, rituximab, and combination chemotherapy in treating patients with newly diagnosed stage II, stage III, or stage IV diffuse large B-cell lymphoma1/2Completed81%/52%NCT00972478^[@CR338]^Vorinostat, R-ICERelapsed or refractory NHLsVorinostat, rituximab, ifosfamide, carboplatin, and etoposide in treating patients with relapsed or refractory lymphoma1Completed70%/29.6%NCT00601718^[@CR339]^Vorinostat, CHOPRelapsed or refractory PTCLPhase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma1Completed93%/93%--^[@CR340]^*BelinostatA pan-HDAC inhibitor*BelinostatRelapsed or refractory aggressive B-NHLsBelinostat in treating patients with relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma2Completed10.5%/0%NCT00303953^[@CR341]^BelinostatRelapsed or refractory PTCL/CTCLA phase II clinical trial of belinostat in patients with relapsed or refractory peripheral and cutaneous T-cell lymphomas (PXD101-CLN-6)2CompletedPTCL, 25%/8.3%; CTCL, 14%/10.3%NCT00274651^[@CR342]^Belinostat, carfilzomibRelapsed or refractory NHLsCarfilzomib plus belinostat in relapsed or refractory NHL1CompletedNANCT02142530--*PanobinostatA pan-HDAC inhibitor*PanobinostatRelapsed or refractory NHLsPanobinostat in treating patients with relapsed or refractory non-Hodgkin's lymphoma2Active, not recruiting21%/NANCT01261247--Panobinostat, lenalidomideRelapsed or refractory HLA phase 2 trial of panobinostat and lenalidomide in patients with relapsed or refractory Hodgkin's lymphoma2Completed16.7%/8.3%NCT01460940--Panobinostat, ICE vs. ICERelapsed or refractory HLPanobinostat plus ifosfamide, carboplatin, and etoposide compared with ifosfamide, carboplatin, and etoposide for relapsed or refractory Hodgkin's lymphoma1/2CompletedNANCT01169636--*RomidepsinA selective HDAC I inhibitor*RomidepsinRelapsed or refractory PTCL/CTCLRomidepsin to treat patients with peripheral T-cell lymphoma and cutaneous T-Cell lymphoma2CompletedPTCL, 38%/18%; CTCL, 34%/5.6%NCT00007345^[@CR343],[@CR344]^Romidepsin, alisertibRelapsed or refractory lymphomaAlisertib and romidepsin in treating patients with relapsed or refractory B-cell or T-cell lymphoma1CompletedNANCT01897012--Romidepsin, duvelisib; bortezomib, duvelisibRelapsed or refractory T-NHLsTrial of duvelisib in combination with either romidepsin or bortezomib in relapsed or refractory T-cell lymphoma1Recruiting--NCT02783625--Romidepsin, lenalidomideRelapsed or refractory NHLs/MMRomidepsin in combination with lenalidomide in adults with relapsed or refractory lymphomas and myeloma1/2Active, not recruiting--NCT01755975--Romidepsin, pralatrexateLymphoid malignanciesRomidepsin plus pralatrexate in relapsed or refractory lymphoid malignancies1/2Recruiting--NCT01947140--Romidepsin, ixazomibRelapsed or refractory PTCLStudy of ixazomib and romidepsin in peripheral T-cell lymphoma1/2Recruiting--NCT03547700--Romidepsin, carfilzomibRelapsed or refractory PTCLEvaluation of the combination of romidepsin and carfilzomib in relapsed or refractory peripheral T-cell lymphoma patients1/2Recruiting--NCT03141203--Romidepsin, pembrolizumabRelapsed or refractory PTCLStudy of pembrolizumab in combination with romidepsin1/2Recruiting--NCT03278782--Romidepsin, azacitidineRelapsed or refractory lymphomaRomidepsin plus azacitidine in relapsed or refractory lymphoid malignancies1/2Active, not recruiting--NCT01998035--Romidepsin, gemcitabineRelapsed or refractory PTCLPhase 2 study of romidepsin plus gemcitabine in the relapsed or refractory peripheral T-cell lymphoma patients2Completed30%/15%NCT01822886^[@CR345]^Romidepsin, ICERelapsed or refractory PTCLRomidepsin, ifosfamide, carboplatin, and etoposide in treating participants with relapsed or refractory peripheral T-cell lymphoma1Completed93%/80%NCT01590732^[@CR346]^Romidepsin, CHOPUntreated PTCLA study of escalating doses of romidepsin in association with CHOP in the treatment of peripheral T-cell lymphoma1/2Completed68%/51%NCT01280526^[@CR347]^Romidepsin, CHOP vs. CHOPUntreated PTCLEfficacy and safety of romidepsin plus CHOP vs. CHOP in patients with untreated peripheral T-cell lymphoma3Active, not recruiting--NCT01796002--*ChidamideA selective HDAC I inhibitor*ChidamideRelapsed or refractory B-NHLsStudy of chidamide as a single-agent treatment for patients with relapse or refractory B-NHLs2Unknown--NCT03245905--ChidamideRelapsed or refractory DLBCL/FLChidamide for patients with relapse or refractory diffuse large B-cell lymphoma and follicular lymphoma2Not yet recruiting--NCT03410004--ChidamideRelapsed or refractpry PTCLA multicenter, open-label, pivotal phase 2 study of chidamide in relapsed or refractory peripheral T-cell lymphoma2Completed28%/14%--^[@CR348]^Chidamide, sintilimabRelapsed or refractory ENKTCLChidamide in combination with sintilimab in relapsed or refractory ENKTCL1/2Recruiting--NCT03820596--Chidamide, DICERelapsed or refractory B-NHLsChidamide plus DICE regimen for patients with relapse or refractory B-cell non-Hodgkin's lymphoma2Unknown--NCT03105596--Chidamide, VDDTRelapsed or refractory DLBCLChidamide combined with VDDT regimen in the relapse or refractory diffuse large B-cell lymphoma2Recruiting--NCT02733380--Chidamide, R-GDPRelapsed or refractory DLBCLChidamide combined with R-GDP in treating patients with relapsed or refractory diffuse large B-cell lymphoma2Recruiting--NCT03373019--Chidamide, R-CHOPRelapsed or refractory DLBCLChidamide with R-CHOP regimen for DLBCL patients2Recruiting--NCT03201471--Chidamide, R-CHOPElderly DLBCLChidamide plus R-CHOP in elderly DLBCL2CompletedNANCT02753647--Chidamide, CHOPUntreated PTCLClinical trial of chidamide combined with CHOP in peripheral T-cell lymphoma patients1CompletedNANCT02809573--Chidamide, CHOPUntreated AITLStudy evaluating the safety and efficacy of chidamide plus CHOP in untreated subjects with angioimmunoblastic T-cell lymphoma2Recruiting--NCT03853044--Chidamide, CHOEPPTCLChidamide combined with CHOEP regimen for peripheral T-cell lymphoma patients2Recruiting--NCT03617432--Chidamide, CPTRelapsed or refractory PTCLChidamide combined with cyclophosphamide, prednisone, thalidomide in treatment of fragile patients with relapse or refractory peripheral T-cell lymphoma2Recruiting--NCT02879526--Chidamide, PETAITLChidamide with prednisone, etoposide, and thalidomide regimen for angioimmunoblastic T-cell lymphoma2Unknown--NCT03273452--Chidamide, PECMRelapsed or refractory PTCLChidamide combined with PECM in relapsed or refractory peripheral T-cell lymphoma2Recruiting--NCT03321890--NA: ORR or CR are not available on the clinicaltrials.gov or from the published article, although the trial has been completed*R-CHOP* rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone, *R-ICE* rituximab, ifosfamide, carboplatin, etoposide, *R-GDP* rituximab, gemcitabine, dexamethasone, cisplatin, *CHOP* cyclophosphamide, doxorubicin, vincristine, prednisolone, *DICE* dexamethasone, ifosfamide, cisplatin, etoposide, *VDDT* vinorelbine, liposomal doxorubicin, dexamethasone and thalidomide, *CHOEP* cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone, *CPT* cyclophosphamide, prednisone, thalidomide, *PET* prednisone, etoposide, thalidomide, *PECM* prednisone, cyclophosphamide, etoposide, methotrexate

### TET2 {#Sec30}

TET2 mediates the oxidation process of 5-methylcytosine (5mC) in gene bodies to 5-hydroxymethylcytosine (5hmC), which plays an important role in transcriptional activation (Fig. [2](#Fig2){ref-type="fig"}).^[@CR298]--[@CR301]^ Experimentally, *TET2* deletion decreased DNA hydroxymethylation at enhancers and reduced the expression of a set of genes in GC B cells associated with GC exit and plasma cell differentiation.^[@CR302]--[@CR307]^ *TET2* was mutated in 12% of DLBCL patients, predominantly in the GCB subtype.^[@CR308]^ *TET2* mutations occur more frequently in T-cell lymphomas, including 47% of AITL and 38% of PTCL-NOS.^[@CR309]--[@CR311]^ A retrospective study indicated that *TET2* mutations in PTCL were associated with advanced-stage disease and high-risk IPI.^[@CR310]^ To date, there are no specific TET2 inhibitors in clinical application. However, the growth inhibition of *TET2*-knockdown DLBCL cells was observed after treatment with a histone deacetylase 3 (HDAC3) inhibitor in vitro.^[@CR312]^ Clinically, AITL patients with *TET2* mutations were reported to have an objective response to azacitidine treatment.^[@CR313]^

### IDH2 {#Sec31}

The isocitrate dehydrogenase (IDH) family, including IDH1, IDH2, and IDH3, catalyzes the oxidative decarboxylation process that transduces isocitrate to α-ketoglutarate.^[@CR314]^ Gain-of-function mutations of *IDH2*^*R172*^ result in the production of 2-hydroxyglutarate (2HG), which inhibits TET enzymes and histone-lysine demethylases and induces the epigenetic modification of DNA.^[@CR315]--[@CR317]^ Altered DNA methylation and downregulated Th1 cell differentiation-associated genes were observed in *IDH2*^*R172*^-mutant AITL.^[@CR316]^ *IDH2*^*R172*^/*TET2* double mutations were found in AITL and correlated with increased follicular T-helper-associated gene expression.^[@CR316]^ For targeted therapy, a phase 1/2 trial (NCT02273739) of enasidenib (also known as AG-221) in subjects with AITL that harbor *IDH2* mutations has been completed.

Histone methylation and targeted therapy {#Sec32}
----------------------------------------

### EZH2 {#Sec33}

Enhancer of zeste homolog 2 (EZH2) functions as a histone methyltransferase and induces transcriptional repression via the trimethylation of H3K27. EZH2 in GC B-cells represses the expression of a set of genes involved in terminal differentiation, such as *PRDM1*, *IRF4*, and *XBP1*, as well as in the negative regulation of cell-cycle progression, such as *CDKN1A* and *CDKN1B*.^[@CR318]--[@CR320]^ Mutations of *EZH2* occur in 25% of FL and 21.7% of GCB-DLBCL but not in ABC-DLBCL.^[@CR319],[@CR321]^ A strong association between *EZH2* mutations and the loss of MHC-I or MHC-II expression was found in DLBCL, especially in GCB-DLBCL.^[@CR322]^ A higher level of H3K27me3 at promoters of *NLRC5* and *CIITA* (MHC-I and MHC-II transactivators) was also found in *EZH2-*mutant cells,^[@CR322]^ indicating the underlying mechanisms of *EZH2* mutation on MHC expression. *EZH2* mutations also occur in T-NHLs. Tazemetostat, a selective inhibitor of EZH2, can effectively block H3K27 methylation and inhibit mutant lymphoma cells.^[@CR323]^ The phase 1 part of a phase 1/2 study (NCT01897571) of tazemetostat in relapsed or refractory B-NHLs was completed and demonstrated acceptable safety and potential antitumor activity (ORR 38% and CR 14%).^[@CR324]^ Additionally, phase 1 studies are assessing the novel EZH2 inhibitors SHR2554 and PF-06821497 in lymphoma (NCT03603951 and NCT03460977).

### KMT2D {#Sec34}

Histone-lysine N-methyltransferase 2D (KMT2D), also called MLL2, is a member of the SET1 family of histone methyltransferases and modulates transcription by H3K4 methylation. Integrative genomic analysis identified that KMT2D-targeted genes included *TNFAIP3*, *TNFRSF14*, and *SOCS3*, which suppress tumorigenesis, and genes involved in cell signaling pathways such as JAK-STAT and BCR.^[@CR325]^ The incidence of inactivating mutations of *KMT2D* is observed in 72% of FL^[@CR319]^ and 30% of DLBCL.^[@CR326]^ *KMT2D* missense mutations lead to a significant reduction in H3K4 methylation in vitro.^[@CR327]^ Recent studies in mice showed that the loss of *KMT2D* resulted in decreased H3K4 methylation and increased tumor development.^[@CR325],[@CR327]^ Though there are no targeted agents for KMT2D, the histone deacetylase inhibitors (HDACis) romidepsin and chidamide showed the ability to restore H3K4me3 levels in *KMT2D* mutant cells in vitro.^[@CR328]^ Chidamide combined with decitabine was observed to induce the apoptosis of Jurkat cells bearing *KMT2D* mutations in vitro and in vivo.^[@CR328]^

Histone acetylation {#Sec35}
-------------------

### CREBBP/EP300 {#Sec36}

The balance between histone acetyltransferases (HATs, including CREBBP and EP300) and HDACs is critical to maintain a normal histone acetylation status in cells. CREBBP and EP300, as histone acetyltransferases, regulate gene transcription by catalyzing the acetylation of the lysine residues of histones. Inactivating mutations in *CREBBP* and *EP300* in GC B-cells decrease p53-mediated tumor suppression and enhance the proto-oncogenic activity of BCL-6.^[@CR329],[@CR330]^ *CREBBP* mutation is also associated with reduced MHC-II expression, which is a key element in antigen presentation, thereby promoting tumor escape from the immune system.^[@CR331]^ *CREBBP* and *EP300* mutations were found in 65% and 15% of FL, respectively. *CREBBP* is mutated in DLBCL, with a significantly higher incidence in the GCB subtype (32% in GCB-DLBCL vs. 13% in ABC-DLBCL). Mutations of *EP300* were observed in 10% of DLBCL.^[@CR329]^ In PTCL-NOS, *CREBBP* and *EP300* are mutated in 4% and 8% of patients, respectively.^[@CR328]^ In NKTCL, *EP300* is mutated in approximately 3.8% of patients.^[@CR243]^

### HDACs {#Sec37}

HDACs are divided into four groups: HDAC I (HDAC 1, 2, 3, and 8), HDAC II (HDAC 4, 5, 6, 7, 9, and 10), HDAC III and HDAC IV.^[@CR332]^ There are three types of HDACis under clinical development: pan-HDACis (vorinostat, belinostat, and panobinostat), selective HDACis (HDAC I inhibitors including romidepsin, chidamide, and entinostat; the HDAC6 inhibitor ricolinostat) and multipharmacological HDACis.^[@CR333]^

Vorinostat (suberoylanilide hydroxamic acid, SAHA), the first HDACi approved by the FDA for treating CTCL, inhibits both HDAC I and HDAC II. A phase 2 trial (NCT00097929) of vorinostat in relapsed DLBCL presented an ORR of 5.6% (CR 5.6%), suggesting that vorinostat monotherapy has limited antitumor activity in relapsed DLBCL. Common AEs were grade 1/2 diarrhea, fatigue, nausea, anemia and vomiting, and grade ≥ 3 AEs including thrombocytopenia and asthenia occurred in 16.7% and 11.1% of the patients, respectively.^[@CR334]^ Another phase 2 trial (NCT00253630) of vorinostat enrolled relapsed or refractory patients with B-NHLs and showed an ORR of 47% (CR 23.5%) in FL, 22% (CR 11%) in MZL, and no response in MCL. Grade ≥ 3 AEs were thrombocytopenia (39%), anemia (11%), leucopenia (11%), and fatigue (9%).^[@CR335]^ Vorinostat in relapsed or refractory CTCL (NCT00091559) had an ORR of 29.7% (CR 0%).^[@CR336]^ A phase 2 trial (NCT00720876) studied the efficacy and safety of vorinostat plus rituximab in NHLs, showing an ORR of 50% (CR 40.9%) in FL, 50% (CR 50%) in MZL, 33% (CR 0%) in MCL and no response in LPL.^[@CR337]^ Vorinostat plus R-CHOP was explored in a phase 1/2 study (NCT00972478) and showed a tendency to improve R-CHOP in untreated advanced-stage DLBCL (ORR 81% and CR 52%); 38% febrile neutropenia and 19% sepsis were reported.^[@CR338]^ Vorinostat in combination with R-ICE was applied in patients with relapsed or refractory NHLs (NCT00601718), and an ORR of 70% (CR 29.6%) was reported. Grade ≥ 3 AEs included febrile neutropenia (27%), infection (27%), and hypophosphatemia (27%) in patients treated at the maximum tolerated dose.^[@CR339]^ A phase 1 trial investigated vorinostat in combination with standard CHOP in untreated PTCL patients and presented an ORR of 93% (CR 93%). Grade ≥ 3 AEs were neutropenia (50%), anemia (17%), and diarrhea (17%) in patients receiving 300 mg three times daily on days 2 to 3.^[@CR340]^

Another pan-HDACi, belinostat (PXD101), was approved by the FDA to treat PTCL. A phase 2 trial (NCT00303953) of belinostat in relapsed or refractory aggressive B-NHLs reported an ORR of 10.5% (CR 0%).^[@CR341]^ Another phase 2 trial (NCT00274651) explored belinostat in relapsed or refractory PTCL or CTCL with an ORR of 25% (CR 8.3%) in PTCL and an ORR of 14% (CR 10.3%) in CTCL. Treatment-related AEs were found in 77% of patients, including nausea (43%), vomiting (21%), infusion site pain (13%), and dizziness (11%).^[@CR342]^ A trial of belinostat combined with carfilzomib in relapsed or refractory NHLs (NCT02142530) is ongoing.

Panobinostat, a pan-HDACi, showed an ORR of 21% in relapsed NHLs (NCT01261247). In relapsed or refractory HL, panobinostat in combination with lenalidomide (NCT01460940) had an ORR of 16.7% (CR 8.3%), while its effect in combination with ICE (NCT01169636) is currently under evaluation.

Romidepsin (FK228), a selective HDAC inhibitor, was approved by the FDA for treating CTCL. A phase 2 trial (NCT00007345) reported an ORR of 38% (CR 18%) in relapsed or refractory PTCL and an ORR of 34% (CR 5.6%) in relapsed or refractory CTCL. Common AEs included nausea, fatigue, transient thrombocytopenia and granulocytopenia.^[@CR343],[@CR344]^ Trials of the combined treatment of romidepsin with other targeted agents, such as alisertib (NCT01897012), duvelisib (NCT02783625), lenalidomide (NCT01755975), pralatrexate (NCT01947140), ixazomib (NCT03547700), carfilzomib (NCT03141203), pembrolizumab (NCT03278782), and azacytidine (NCT01998035), in relapsed or refractory NHLs are ongoing. A phase 2 trial (NCT01822886) of romidepsin plus gemcitabine in relapsed or refractory PTCL showed an ORR of 30% (CR 15%).^[@CR345]^ A phase 1 trial (NCT01590732) of romidepsin plus ICE in relapsed or refractory PTCL had an ORR of 93% (CR 80%), and the most common grade ≥ 3 AEs were thrombocytopenia (83%), anemia (50%), neutropenia (44%), fatigue (33%), nausea or vomiting (33%), infections (28%), dyspnea (17%), and transaminitis (11%).^[@CR346]^ Of note, a phase 1/2 trial (NCT01280526) of romidepsin plus CHOP induced an ORR of 68% (CR 51%) in untreated PTCL.^[@CR347]^ Thus, a randomized phase 3 trial (NCT01796002) of romidepsin plus CHOP vs CHOP in untreated PTCL is ongoing.

Chidamide, a selective HDAC I inhibitor, is being evaluated in relapsed or refractory B-NHLs (NCT03245905 and NCT03410004). In a phase 2 trial of relapsed or refractory PTCL, chidamide showed an ORR of 28% (CR 14%). Grade ≥ 3 AEs were thrombocytopenia (22%), leucopenia (13%), and neutropenia (11%).^[@CR348]^ A trial of chidamide in combination with sintilimab is ongoing in relapsed or refractory NKTCL (NCT03820596). Phase 2 trials of chidamide in combination with chemotherapy, such as dexamethasone, ifosfamide, cisplatin, and etoposide (DICE) (NCT03105596), vinorelbine, liposomal doxorubicin, dexamethasone and thalidomide (VDDT) (NCT02733380), R-GDP (NCT03373019), and R-CHOP (NCT03201471) in relapsed or refractory B-NHLs, as well as R-CHOP (NCT02753647) in untreated elderly DLBCL patients, are ongoing. In T-NHLs, the efficacy of chidamide combined with CHOP (NCT02809573 and NCT03853044); cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone (CHOEP) (NCT03617432); cyclophosphamide, prednisone, and thalidomide (CPT) (NCT02879526); prednisone, etoposide, and thalidomide (PET) (NCT03273452); and prednisone, etoposide, cyclophosphamide, and methotrexate (PECM) (NCT03321890) are under evaluation.

Although epigenetic alterations show clinical significance, modulators specifically targeting these alterations remain to be developed. Demethylation agents and HDACis have presented clinical efficacy in many lymphoma subtypes. However, the exact mechanisms of action remain unclear, and biomarkers to predict clinical effects need to be further explored. Moreover, monotherapy with epigenetic agents may have limited efficacy in lymphoma in early phase studies. Trials in combination with chemotherapy or other small molecules have demonstrated potent efficacy and acceptable safety and warrant further investigation.

Tumor microenvironment and checkpoint-related targeted therapy {#Sec38}
==============================================================

In addition to tumor cells themselves, the tumor microenvironment plays an important role in lymphoma progression. Immunotherapeutic agents can effectively activate the immune system, leading to tumor regression, and have improved clinical outcomes in lymphoma patients.^[@CR349]--[@CR352]^ In addition, checkpoint inhibitors combined with CAR-T therapy, epigenetic modulators, radiotherapy, and BTK inhibitors have shown striking efficacy in refractory lymphoma.^[@CR353]--[@CR355]^

PD-1/PD-L1 {#Sec39}
----------

Programmed cell death-1 (PD-1, also known as CD279) is a member of the immunoglobulin superfamily and functions as an important immune checkpoint that suppresses excessive immune responses.^[@CR6]^ PD-1 is mainly expressed on activated T cells and a small number of B cells, NK cells, activated monocytes, and dendritic cells but is not expressed on naïve T cells. The persistent stimulation of PD-1 on T cells can lead to T-cell exhaustion.^[@CR356],[@CR357]^ The ligands of PD-1 include PD-L1 (also known as B7-H1, CD274) and PD-L2 (also known as B7-DC, CD273).^[@CR358],[@CR359]^ PD-L1 is expressed on B cells, T cells, dendritic cells, and macrophages. PD-L2 is expressed mainly on dendritic cells, macrophages, mast cells, and certain B cells in response to IL-4 and IFN.^[@CR358],[@CR359]^ In addition to those immune cells, PD-L1 is expressed on tumor cells and protects them from immune surveillance; a high level of PD-L1 on tumor cells is associated with poor prognosis in patients.^[@CR360]--[@CR363]^ Therefore, PD-1/PD-L1 pathway blockade can promote T-cell activation and cytokine production and preserve the antitumor capacity of T cells in the treatment of lymphomas.^[@CR364]^

PD-1 is overexpressed in the tumor-infiltrating lymphocytes (TILs) of HL,^[@CR365]^ and 94--100% of refractory or relapsed HL cases are positive for PD-L1.^[@CR353],[@CR366]^ The 9p24.1 amplification is frequently detected in HL, resulting in increased PD-L1 and PD-L2 expression on Hodgkin and Reed--Sternberg (HRS) cells.^[@CR367]^ Moreover, the amplified 9p24.1 region contains the *JAK2* locus, further enhancing PD-L1 expression in HRS cells.^[@CR367]^ In FL, though PD-1 expression on TILs is abundant, PD-L1 expression on lymphoma cells is low (0--5%).^[@CR368]--[@CR375]^ In DLBCL, the positive rate of PD-1 was 39.5--68.6%,^[@CR376]--[@CR380]^ and the positive rate of PD-L1 was 24--75%.^[@CR375],[@CR380]--[@CR382]^ Moreover, the number of PD-1^+^ TILs is higher in the GCB subtype, and patients with PD-L1^+^ tumor cells have inferior OS compared to those with PD-L1^-^ tumor cells.^[@CR379]^ Soluble PD-L1 (sPD-L1), independent of IPI, has been reported to be an adverse prognostic factor for DLBCL. Similar to PD-1, sPD-L1 is elevated in DLBCL patients at diagnosis and returns to normal when patients achieve CR. Thus, sPD-L1 is an effective predictor of DLBCL.^[@CR382]^ In PTCL, PD-1 is positive in 70% and 61% of AITL and PTCL-NOS, respectively, and PD-1 is rarely detected in ALCL. PD-L1 is expressed in 46% of ALK^+^ ALCL and in 46% of ALK^-^ ALCL. In contrast, there is no PD-L1 expression in AITL and PTCL-NOS.^[@CR383]^

The targeted drugs and clinical trials related to PD-1 are shown in Table [6](#Tab6){ref-type="table"}. Nivolumab and pembrolizumab were approved by the FDA to treat relapsed or refractory HL.^[@CR366],[@CR377],[@CR384],[@CR385]^ In a phase 1 trial (NCT01592370) of nivolumab in relapsed or refractory HL, the ORR was 87% (CR 17%), and the 24-week PFS was 86%.^[@CR349]^ In a phase 2 trial (NCT02181738), the efficacy of nivolumab was evaluated in relapsed or refractory HL. At a median follow-up of 8.9 months, the ORR was 66.3% (CR 9%), and the 6-month PFS and OS were 77% and 99%, respectively.^[@CR350]^ In relapsed or refractory NHLs, a phase 1 trial of nivolumab (NCT01592370) showed an ORR of 40% (CR 10%) in FL, 36% (CR 18%) in DLBCL, and 17% (CR 0%) in T-NHLs.^[@CR386]^ Another phase 2 trial (NCT02038933) of nivolumab in ASCT-failed DLBCL showed an ORR of 10.3% (CR 3.4%). Nivolumab in relapsed or refractory ALK^+^ ALCL (NCT03703050) and PTCL (NCT03075553) is currently under clinical evaluation in phase 2 trials. In relapsed or refractory PCNSL and testicular lymphoma (NCT02857426), nivolumab showed an ORR of 100% (CR 80%).^[@CR351]^ In addition, nivolumab combined with BV (NCT02572167) in relapsed or refractory HL had a reported ORR of 82% (CR 16%),^[@CR387]^ and this combination in NHLs (NCT02581631) is ongoing. Nivolumab combinations with other targeted agents such as lenalidomide in relapsed or refractory lymphoma (NCT03015896), rituximab in FL (NCT03245021), cabiralizumab in PTCL (NCT03927105), and in combination with chemotherapy, such as rituximab, gemcitabine, and oxaliplatin (R-GemOx) in elderly lymphoma patients (NCT03366272), R-CHOP (NCT03704714), and rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-R-EPOCH) (NCT03749018) in aggressive NHLs are ongoing.Table 6Targeted drugs and clinical trials related to PD-1DrugDiseaseTrial namePhaseStatusORR/CRNCT\#Reference*NivolumabA human monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2*NivolumabRelapsed or refractory HLPD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma1Completed87%/17%NCT01592370^[@CR349]^NivolumabRelapsed or refractory HLNivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicenter, multicohort, single-arm phase 2 trial2Completed66.3%/9%NCT02181738^[@CR350]^NivolumabRelapsed or refractory NHLs/MMNivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase 1 study1CompletedFL, 40%/10%; DLBCL, 36%/18%; T-NHLs, 17%/0%NCT01592370^[@CR386]^NivolumabRelapsed or refractory DLBCL (failed or not eligible for ASCT)Study of nivolumab in patients with relapsed or refractory diffuse large B-cell lymphoma that have either failed or are not eligible for autologous stem cell transplant2CompletedASCT-failed, 10.3%/2.9%; ASCT ineligible, 3.4%/0%NCT02038933--NivolumabRelapsed or refractory ALK^+^ ALCLPhase 2 trial of nivolumab for pediatric and adult relapsed or refractory ALK^+^ anaplastic large cell lymphoma, for evaluation of response in patients with progressive disease (cohort 1) or as consolidative immunotherapy in patients in complete remission after relapse (cohort 2)2Recruiting--NCT03703050--NivolumabRelapsed or refractory PTCLNivolumab in treating patients with relapsed or refractory peripheral T-cell lymphoma2Active, not recruiting--NCT03075553--NivolumabRelapsed or refractory PCNSL/primary testicular lymphomaPD-1 blockade with nivolumab in relapsed or refractory primary central nervous system and testicular lymphoma2Completed100%/80%NCT02857426^[@CR351]^Nivolumab, BVRelapsed or refractory HLInterim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin's lymphoma1/2Completed82%/61%NCT02572167^[@CR387]^Nivolumab, BVNHLsAn investigational immunotherapy effectiveness and safety study of nivolumab in combination with brentuximab vedotin to treat non-Hodgkin's lymphomas1/2Active, not recruiting--NCT02581631--Nivolumab, lenalidomideRelapsed or refractory NHLs/HLNivolumab and lenalidomide in treating patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma1/2Recruiting--NCT03015896--Nivolumab, rituximabFLNivolumab plus rituximab in first-line follicular lymphoma grade 1-3A1Recruiting--NCT03245021--Nivolumab, cabiralizumabPTCLNivolumab and the antagonistic CSF-1R monoclonal antibody cabiralizumab in patients with relapsed or refractory peripheral T-cell lymphoma2Recruiting--NCT03927105--Nivolumab, rituximab, gemcitabine, oxaliplatinNHLs (elderly patients)Nivolumab with gemcitabine, oxaliplatin, rituximab in relapsed or refractory elderly lymphoma patients2/3Recruiting--NCT03366272--Nivolumab, R-CHOPAggressive NHLsNivolumab and combination chemotherapy in treating participants with diffuse large B-cell lymphoma1/2Recruiting--NCT03704714--Nivolumab, DA-R-EPOCHAggressive NHLsNivolumab with DA-REPOCH chemotherapy regimen in treating patients with aggressive B-cell non-Hodgkin's lymphoma2Recruiting--NCT03749018--*PembrolizumabA humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2*PembrolizumabRelapsed or refractory HLPD-1 blockade with pembrolizumab in patients with classical Hodgkin's lymphoma after brentuximab vedotin failure1Completed65%/16%NCT01953692^[@CR353]^PembrolizumabRelapsed or refractory HLPhase 2 study of the efficacy and safety of pembrolizumab for relapsed or refractory classic Hodgkin's lymphoma2Completed69%/22.4%NCT02453594^[@CR366]^PembrolizumabTransformed DLBCL/relapsed or refractory CLLPembrolizumab in patients with CLL and Richter transformation or with relapsed CLL2Completedtransformed DLBCL, 41%/11%; CLL, 0%/0%NCT02332980^[@CR388]^PembrolizumabRelapsed or refractory PMBCLSafety and tolerability of pembrolizumab in patients with relapsed or refractory primary mediastinal large B-cell lymphoma1Completed41%/11.8%NCT01953692^[@CR389]^PembrolizumabRelapsed or refractory GZL/extranodal DLBCLPembrolizumab in relapsed or refractory gray-zone lymphoma, primary central nervous system lymphoma, and other extranodal diffuse large B-cell lymphomas2Recruiting--NCT03255018--PembrolizumabUntreated B-NHLsPembrolizumab in untreated B-cell non-Hodgkin's lymphoproliferative diseases2Recruiting--NCT03498612--PembrolizumabRelapsed or refractory stage IB-IVB MF/SSA phase 2 study of pembrolizumab for the treatment of relapsed or refractory mycosis fungoides/Sézary syndrome2Completed37.5%/8.3%NCT02243579--PembrolizumabStage IB-IV MFPembrolizumab in treating patients with stage IB-IV mycosis fungoides2Recruiting--NCT03695471--PembrolizumabEarly stage NKTCL, nasal typeStudy of pembrolizumab in patients with early stage NK/T-Cell lymphoma, nasal type2Recruiting--NCT03728972--Pembrolizumab, umbralisibRelapsed or refractory B-NHLs/CLLCombination of pembrolizumab with umbralisib in patients with relapsed or refractory CLL and B-NHLs1Recruiting--NCT03283137--Pembrolizumab, lenalidomideRelapsed NHLs/HLEfficacy and safety study of combination of pembrolizumab and lenalidomide, in patients with relapsed non-Hodgkin's and Hodgkin's lymphoma1/2Active, not recruiting--NCT02875067--Pembrolizumab, mogamulizumabRelapsed or refractory NHLs/HLPembrolizumab and mogamulizumab in treating patients with relapsed or refractory lymphomas1/2Recruiting--NCT03309878--Pembrolizumab, rituximabRelapsed or refractory DLBCL/FLPembrolizumab and rituximab in treating patients with relapsed or refractory diffuse large B-cell lymphoma or follicular lymphoma2Recruiting--NCT03401853--PralatrexateRelapsed or refractory mature T- and NK-cell NHLs/MFPembrolizumab and pralatrexate in treating participants with relapsed or refractory peripheral T-cell lymphoma1/2Recruiting--NCT03598998--Pembrolizumab, tisagenlecleucelRelapsed or refractory DLBCLStudy of pembrolizumab in combination with tisagenlecleucel in relapsed or refractory diffuse large B-cell lymphoma patients1Recruiting--NCT03630159--Pembrolizumab, EBRTRelapsed or refractory NHLsPembrolizumab and external beam radiation therapy in treating participants with relapsed or refractory non-Hodgkin lymphomas2Recruiting--NCT03210662--Pembrolizumab, radiotherapyRelapsed or refractory MF/SSA trial assessing the effect of pembrolizumab combined with radiotherapy in patients with relapsed or refractory, specified stages of cutaneous T-cell lymphoma mycosis fungoides/Sézary syndrome (PORT)2Recruiting--NCT03385226--NA: ORR or CR are not available on the clinicaltrials.gov or from the published article although the trial has been completed*BV* brentuximab vedotin, *R-CHOP* rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone, *DA-R-EPOCH* rituximab, dose-adjusted EPOCH, *GZL* gray-zone lymphoma, *EBRT* external beam radiotherapy

Pembrolizumab, a humanized mAb of PD-1, showed an ORR of 65% (CR 16%) in a phase 1 trial (KEYNOTE-013, NCT01953692) of relapsed or refractory HL^[@CR353]^ and an ORR of 69% (CR 22.4%) in a phase 2 trial (KEYNOTE-087, NCT02453594).^[@CR366]^ Pembrolizumab induced an ORR of 41% (CR 11%) in transformed DLBCL and showed no response in relapsed or refractory CLL in a phase 2 trial (NCT02332980).^[@CR388]^ In a phase 1 trial (NCT01953692), pembrolizumab was evaluated in relapsed or refractory PMBCL, and the ORR was 41% (CR 11.8%).^[@CR389]^ Trials of pembrolizumab in relapsed or refractory gray-zone lymphoma and PCNSL (NCT03255018) and in untreated B-NHLs (NCT03498612) are ongoing. In a study of relapsed or refractory NKTCL patients who failed asparaginase treatment or ASCT, pembrolizumab presented an ORR of 100% (CR 71.4%).^[@CR352]^ In a phase 2 trial (NCT02243579) of pembrolizumab in advanced relapsed or refractory MF and SS, the ORR was 37.5% (CR 8.3%). Thus, trials of pembrolizumab in MF (NCT03695471) and NKTCL (NCT03728972) are ongoing. Pembrolizumab in combination with other targeted agents, such as umbralisib (NCT03283137), lenalidomide (NCT02875067), mogamulizumab (NCT03309878), rituximab (NCT03401853), pralatrexate (NCT03598998), CAR-T (tisagenlecleucel, NCT03630159), and radiation (NCT03210662 and NCT03385226), are under evaluation.

CTLA-4 {#Sec40}
------

CTLA-4, a member of the immunoglobulin family receptors, together with CD28, are homologous receptors of CD4^+^ and CD8^+^ T cells. Both receptors share a pair of ligands (CD80/CD86) expressed on the surface of antigen-presenting cells (APCs). In contrast with CD28, the signal of CTLA-4 suppresses the activation of T cells, and the affinity of CTLA-4 and CD80 is higher than that of CD28 and CD80. In addition to APCs, CTLA-4 is also present in resting T cells in the form of intracellular vesicles and expressed on the cell membrane surface when T cells are activated.^[@CR390]^ The CTLA4-CD86 protein recruits and activates Tyk2, leading to STAT3 activation and the expression of genes involved in immune suppression and tumor growth. Although the CTLA-4 antibody ipilimumab^[@CR391]^ has become a first-line therapy in metastatic melanoma,^[@CR392],[@CR393]^ the application of the CTLA-4 antibody still needs to be explored in hematological malignancies.^[@CR394]^ The phase 1 part of a phase 1/2 trial (NCT00089076) of ipilimumab in relapsed or refractory B-NHLs induced an ORR of 11.1% (CR 5.6%).^[@CR395]^ Trials of ipilimumab combined with other agents, such as nivolumab (NCT02408861) in HIV-associated HL, are ongoing. A trial of tremelimumab, another CTLA-4 mAb, in combination with durvalumab in relapsed or refractory DLBCL (NCT02549651) was completed.

CD47/SIRPα {#Sec41}
----------

CD47 is a new immune checkpoint that is expressed in normal cells and upregulated in various tumors.^[@CR396]--[@CR398]^ Its ligand SIRPα is expressed on myeloid cells (monocytes, macrophages, and myeloid dendritic cells). CD47/SIRPα mainly regulates innate immune cell activity and sends out a "do not eat me" signal to escape the attack of innate immune cells.^[@CR399]^ MYC can upregulate the expression of the *CD47* gene by binding to the promoter of *CD47*. The downregulation of *MYC* gene expression in a murine model led to decreased CD47 expression.^[@CR400]^ CD47 is upregulated in various NHLs (DLBCL, MCL, FL, and CLL) and is associated with poor clinical outcomes in patients.^[@CR401]^ Targeting CD47 can reduce liver and central nervous system metastasis in Raji-engrafted mice,^[@CR402]^ suggesting the association of CD47 with the extranodal metastasis of lymphoma cells. TTI-621 (an anti-CD47 antibody) enhances macrophage-mediated phagocytosis and can effectively control B-NHL growth in xenograft murine models. Another anti-CD47 antibody, Hu5F9-G4, combined with rituximab, is effective in the treatment of NHLs. In the phase 1 part of a phase 1/2 trial (NCT02953509), 22 relapsed or refractory DLBCL and FL patients were enrolled. The ORRs and CR rates were 40% and 33% in DLBCL and 71% and 43% in FL, respectively. The most common AEs were anemia and infusion reactions.^[@CR403]^

OX40/OX40L {#Sec42}
----------

OX40 is a member of the TNFR superfamily. Under physiological conditions, it is mainly expressed in activated T cells and is more abundant in CD4^+^ T cells than in CD8^+^ T cells. OX40L, the ligand of OX40, is a type II transmembrane protein and is expressed in a variety of APCs (B-cells, dendritic cells, and macrophages), activated T cells, vascular endothelial cells and mast cells.^[@CR404]--[@CR406]^ The OX40L-OX40 signaling pathway is the basis for effector T-cell proliferation and memory T-cell development. However, the OX40L-OX40 axis can promote immune escape and tumor growth.

Experimentally, an OX40 agonist showed antitumor activity in combination with other drugs. Intratumoral injection of anti-CTLA-4 and OX40 agonists depleted tumor-infiltrating Tregs in murine lymphoma models.^[@CR407]^ A phase 1 clinical study (NCT03636503) of PF-04518600 (the OX40 agonist) in combination with utomilumab (4-1BB agonist) and rituximab or in combination with avelumab (anti-PD-L1) and rituximab is ongoing in aggressive B-NHLs.

Other immune checkpoint molecules {#Sec43}
---------------------------------

T-cell immunoglobulin and ITIM domain (TIGIT) is a coinhibitory receptor that is expressed on NK cells and different types of T cells, including effector and memory T cells and Tregs.^[@CR408]--[@CR410]^ The ligands of TIGIT, CD155 (PVR) and CD112 (PVRL2, nectin-2) are expressed on APCs, T cells, and tumor cells.^[@CR411],[@CR412]^ In NHL, TIGIT and PD-1 are frequently coexpressed on TILs. Approximately 78--83% of CD8^+^ and 69--70% of CD4^+^ T effector memory cells (TEMs) are simultaneously positive for these two inhibitory molecules, and these TEMs have limited capability for IL-2, IFN-γ, and TNF-α secretion.^[@CR413]^ In FL, TIGIT is mainly expressed by CD8^+^ effector and memory T cells and is related to advanced disease stage.^[@CR414]^ TIM-3 inhibits Th1 cell responses,^[@CR415]^ and its antibodies have been found to potently enhance antitumor immunity.^[@CR416]^ An increased number of TIM-3^+^ T cells is related to the unfavorable prognosis of FL patients.^[@CR414]^ TIM-3 is preferentially expressed on the microvascular endothelial cells of lymphoma, suppresses the activation of CD4^+^ T lymphocytes and facilitates the progression of lymphoma by mediating immune evasion.^[@CR417]^

Indoleamine 2,3-dioxygenase (IDO), a known immune suppressor, plays a role in human mesenchymal stromal cells (MSCs) to regulate immunity in the tumor microenvironment. IDO^+^ MSCs can inhibit T-cell proliferation in vitro. In a lymphoma murine model, IDO^+^ MSCs could enhance tumor growth, which could be reversed by the IDO inhibitor D-1-methyl-tryptophan (D1-MT).^[@CR418]^ Since MSCs secrete IDO to further suppress T-cell immune responses, umbilical cord-derived MSCs genetically secrete TandAb (a tetravalent bispecific antibody with two CD3 and two CD19 binding sites). In vitro, TandAb can induce the specific lysis of CD19^+^ cell lines in the presence of T cells, and an IDO inhibitor could enhance the cytotoxicity of T cells triggered by MSC-TandAb.^[@CR419]^ Clinical studies of IDO inhibitors in lymphomas are still lacking. V-domain immunoglobulin suppressor of T-cell activation (VISTA) is another checkpoint molecule that has a strong inhibitory influence on T cells.^[@CR420]^ VISTA is constitutively expressed in CD11b^high^ myeloid cells and is expressed at a low level on T cells and Foxp3^+^CD4^+^ Treg cells.^[@CR421]^ In animal models with solid tumors, myeloid-derived suppressor cells (MDSCs) infiltrating tumors were found to highly express VISTA compared to peripheral blood cells.^[@CR422],[@CR423]^ In a murine model of squamous cancer, anti-VISTA monotherapy increased the infiltration and activation of T cells. A clinical trial (NCT02812875) evaluating the efficacy and safety of CA-107 (targeting PD-L1, PD-L2, and VISTA) for the treatment of lymphoma is ongoing.

Adoptive T/NK-cell therapy {#Sec44}
==========================

Adoptive T-cell transfer is an emerging immunotherapy in a variety of tumors, particularly CAR-T therapy. In 2017, the FDA approved tisagenlecleucel (a CD19-specific 4-1BB-CAR construct) for the treatment of relapsed or refractory B-ALL, and in 2018, the FDA approved axicabtagene ciloleucel (a CD19-specific CD28-CAR construct) for the treatment of relapsed or refractory DLBCL. Another CD19 CAR-T cell line, lisocabtagene maraleucel (a CD19-specific 4-1BB-CAR construct), is also undergoing evaluation.

CAR-T therapy in lymphoma {#Sec45}
-------------------------

In a single-arm, multicenter clinical trial (NCT02348216) for relapsed or refractory DLBCL, transformed FL, and PMBCL, axicabtagene ciloleucel had an ORR of 83% (CR 58%) and median PFS of 5.9 months.^[@CR424]^ In another clinical trial (NCT02030834) of relapsed or refractory B-NHLs, tisagenlecleucel induced an ORR of 64.3% (CR 57.1%). Moreover, all CR patients were still in remission at 6 months.^[@CR425]^ In a phase 2 trial (NCT02445248) of tisagenlecleucel in relapsed or refractory DLBCL, the ORR was 52% (CR 40%), with a 1-year RFS of 65%.^[@CR426]^

In addition to axicabtagene ciloleucel and tisagenlecleucel, lisocabtagene maraleucel was tested in relapsed or refractory DLBCL, PMBCL, FL, and MCL (TRANSCEND, NCT02631044) and showed a CR rate of 80% in high-grade B-cell lymphoma (double/triple hit) and DLBCL.^[@CR427],[@CR428]^ A phase 1 dose-escalation study (NCT03355859) of anti-CD19 JWCAR029 was conducted in refractory B-NHLs, and the ORR was 100%, with 6 of 9 (66.7%) evaluable patients achieving CR. In this study, core needle biopsy was performed on tumor samples on day 11 after CAR-T cell infusion. Further RNA sequencing of these tumor samples identified gene expression signatures differentially enriched in complete and partial remission patients. Increased tumor-associated macrophage infiltration was negatively associated with remission status.^[@CR429]^

In addition to studies targeting CD19 CAR-T cells, studies on CD20, CD22, and CD30 CAR-T cell therapy have also been carried out. In a phase 2 study (NCT01735604) of anti-CD20 CAR-T therapy, the ORR was 81.8% (CR 54.5%).^[@CR430]^ In a phase 1 trial (NCT02315612), anti-CD22 CAR-T cells were evaluated in patients with B-cell malignancies resistant to CD19 CAR-T cells and showed a CR rate of 73%, with a median remission duration of 6 months.^[@CR431]^ A phase 1 trial (NCT01306146) of anti-CD30 CAR-T cells showed a CR rate of 28.6% in relapsed HL and a CR rate of 50% in ALCL.^[@CR432]^

Anti-CD4 CAR-T cells could control the growth of tumors in a xenograft murine model of ALCL.^[@CR433]^ However, this therapy also faces the challenge of CAR-T cells sharing antigens with normal T cells and can recognize and kill three types of cells: tumor T cells, normal T cells, and CAR-T cells. This problem can lead to the "auto-phase killing" of CAR-T cells, while CAR-T cells targeting normal T cells may lead to severe infection in patients.^[@CR434]^ Therefore, reducing the side effects of CAR-T cells in T-NHLs has become the focus of research. Moreover, using CRISPR/Cas9 gene-editing technology, generating CAR-T cells (also known as UCART7) that lack CD7 and TCR alpha-chain expression could target CD7^+^ T-cell malignancies and reduce mutual attacks between CAR-T cells.^[@CR435]^

Although CAR-T therapy has been successful in the treatment of hematological malignancies, there are still patients who do not respond to the treatment, as well as some patients presenting signs of AEs such as severe cytokine release syndrome (CRS), infection, and neurotoxicity. Therefore, identifying patients who may respond to CAR-T therapy and patients who may have serious side effects during treatment has become a research hotspot.

CAR-NK therapy {#Sec46}
--------------

With the continuous development of CAR-T therapy, CAR-NK cells have also become a focus of attention. NK cells are cytotoxic immune cells that form a small fraction of normal lymphocytes and can trigger the innate immune response against tumor cells and virus-infected cells.^[@CR436]^ Studies have shown that NK cells have a nonnegligible role in tumor monitoring, and loss of NK cells leads to tumor progression.^[@CR437]--[@CR439]^ Because NK and T cells are functionally similar, NK cells can also be used to attack tumors. Many researchers hope that CAR-NK cells can achieve results in tumor treatment similar to CAR-T cells. Compared with T cells, NK cells kill tumor cells in a nonantigen-dependent manner. Moreover, NK cells express CD56 and CD7 but lack the expression of CD3, TCR, and CD5.^[@CR440]^ When used in the treatment of T-NHLs, the fratricide of CAR-NK cells was reduced.^[@CR441]^

Anti-CD19 cord blood (CB)-derived NK cells were evaluated in a xenograft lymphoma murine model and significantly prolonged the survival of mice.^[@CR442]^ In another study, anti-CD5 CAR-NKs had potent antitumor activity against a variety of T-NHLs and primary tumor cells in vitro and in a murine model.^[@CR443]^ Clinical trials (NCT03383965, NCT029170083 and NCT03049449) of CAR-NK cells targeting CD19, CD20, and CD22 have begun for the treatment of B-NHLs. In addition, a phase 1 trial (NCT02742727) of anti-CD7 CAR-NK for the treatment of T-cell malignancies is ongoing.

Specific oncogenes and proteins related to targeted therapy {#Sec47}
===========================================================

Specific oncogenes, such as MYC, BCL-2, and BCL-6, converge proliferation, differentiation, and anti-apoptotic signaling in lymphoma cells and play critical roles in lymphomas. Moreover, lymphomas that have a concomitant translocation of *MYC* and *BCL-2* or *BCL-6* represent high-grade B-cell lymphoma and are resistant to conventional R-CHOP chemotherapy. The tumor suppressor gene p53 is involved in the process of DNA repair, and the depletion or mutation of *p53* promotes lymphoma progression and drug resistance. The t(2;5)(p23;q35) translocation results in the NPM1/ALK fusion protein and then activates the downstream oncogenic transcription factor STAT3, enhancing lymphoma cell proliferation and growth. Thus, these specific oncogenes are greatly involved in lymphoma genesis and progression, and targeting these genes and their downstream pathways might retard tumor progression and improve patient survival.

MYC {#Sec48}
---

*MYC* is a family of three proto-oncogenes that function as important regulators of cell proliferation, growth, differentiation, and apoptosis. They encode the related transcription factors MYC, MYCN, and MYCL, also known as c-MYC, N-MYC, and L-MYC, respectively.^[@CR444]^ The *Ig-MYC* translocation is the most common type of *MYC* alteration and can cause MYC overexpression.^[@CR445]^ MYC is expressed at the pro-B and pre-B-cell stages and in a minority of GC B-cells.^[@CR446]--[@CR448]^ Additionally, MYC is frequently overexpressed in lymphomas of GC origin. In BL, the t(8;14) translocation is found in approximately 80% of all patients.^[@CR449]^ In DLBCL, MYC overexpression is shown in 30--50% of patients.^[@CR450],[@CR451]^ *MYC* translocations preferentially occur in GCB-DLBCL over ABC-DLBCL (17.7% vs. 6.7%).^[@CR450]^ A high level of MYC is associated with a low treatment response and poor prognosis in DLBCL patients treated with R-CHOP and may also lead to an increased relapse rate in the central nervous system.^[@CR452],[@CR453]^

Studies have shown the potential effect of MYC-associated agents, including targeting cell-cycle-associated vulnerabilities, transcription, RNA processing and turnover, ribosome biogenesis and translation, as well as MYC-induced metabolic perturbations.^[@CR454]^ The mitotic spindle-regulatory kinases Aurora-A and Aurora-B are both overexpressed in MYC-associated B-cells, and Aurora-A promotes the stabilization of MYC and MYCN.^[@CR455],[@CR456]^ The targeted drugs and clinical trials related to specific oncogenes and proteins are shown in Table [7](#Tab7){ref-type="table"}. A phase 1 trial (NCT01897012) of alisertib combined with romidepsin in relapsed or refractory NHLs is ongoing.Table 7Targeted drugs and clinical trials related to specific oncogenes and proteinsDrugDiseaseTrail namePhaseStatusORR/CRNCT\#Reference*MYCAlisertiba selective Aurora-A inhibitor*Alisertib, romidepsinRelapsed or refractory NHLsAlisertib and romidepsin in treating patients with relapsed or refractory B-cell or T-cell lymphomas1CompletedNANCT01897012--*BCL-2NavitoclaxA BCL-2, BCL-XL, and BCL-w inhibitor*Navitoclax, rituximabLymphoid cancersSafety study of navitoclax in combination with rituximab in lymphoid cancers1Active, not recruiting--NCT00788684--*VenetoclaxA highly selective BH3 mimetic*Venetoclaxrelapsed or refractory NHLs/CLLA phase 1 study evaluating the safety and pharmacokinetics of venetoclax in subjects with relapsed or refractory non-Hodgkin's lymphoma and chronic lymphocytic leukemia1Active, not recruitingMCL, 75%/21%; FL, 38%/14%; DLBCL, 18%/12%; MZL, 67%/0%NCT01328626^[@CR472]^Venetoclax, bendamustine, rituximabRelapsed or refractory FLA study evaluating the safety and efficacy of venetoclax plus bendamustine and rituximab in comparison with bendamustine plus rituximab or venetoclax plus rituximab in participants with relapsed and refractory FL2CompletedVenetoclax, rituximab, 32.7%/13.2%; venetoclax, BR, 45.1%/27.5%; BR, 51%/23.5%NCT02187861--Venetoclax, ibrutinibMCLStudy of venetoclax combined with ibrutinib in subjects with mantle cell lymphoma (SYMPATICO)3Active, not recruiting--NCT03112174--Venetoclax, RO6870810, rituximabRelapsed or refractory DLBCL/high-grade B-cell lymphomaA study to evaluate safety, pharmacokinetics, and clinical activity of combination of venetoclax and RO6870810, With or without rituximab, in participants with relapsed or refractory DLBCL and high-grade B-cell lymphoma1Active, not recruiting--NCT03255096--Venetoclax, R-CHOP/G-CHOPB-NHLsA safety and pharmacokinetics study of venetoclax in participants with non-Hodgkin's lymphoma1/2CompletedPhase 1 part: venetoclax, R-CHOP, 87.5%/79.2%; venetoclax, G-CHOP, 87.5%/78.1%NCT02055820^[@CR473]^Venetoclax, DA-R-EPOCHAggressive B-NHLsStudy of venetoclax plus DA-R-EPOCH for the treatment of aggressive B-cell lymphomas1Active, not recruiting--NCT03036904--*TP53IdasanutlinA potent and selective MDM2 antagonist*Idasanutlin, obinutuzumab/rituximab, venetoclaxRelapsed or refractory FL/DLBCLA study of obinutuzumab in combination with idasanutlin and venetoclax in participants with relapsed or refractory follicular lymphoma or rituximab in combination with idasanutlin and venetoclax in participants with relapsed or refractory diffuse large B-cell lymphoma1/2Active, not recruiting--NCT03135262--*SelinexorAn inhibitor of exportin 1*SelinexorAdvanced hematological cancerSafety study of the selective inhibitor of nuclear export selinexor in patients with advanced hematological cancer1Completed31%/6%NCT01607892^[@CR489]^Selinexor, chemotherapyAdvanced B-NHLsSelinexor plus chemotherapy in treating patients with advanced B-cell non-Hodgkin's lymphoma1/2Recruiting--NCT03147885--*ALKCrizotinibThe first-generation ALK tyrosine kinase inhibitor*CrizotinibRelapsed ALK^+^ lymphomasPilot study of crizotinib in relapsed ALK^+^ Lymphomas2Recruiting--NCT02419287--*BrigatinibThe second-generation ALK tyrosine kinase inhibitor*BrigatinibRelapsed or refractory ALK^+^ ALCLBrigatinib in relapsed or refractory ALK^+^ anaplastic large cell lymphoma2Recruiting--NCT03719898--*LorlatinibThe third-generation ALK tyrosine kinase inhibitor*LorlatinibRelapsed ALK^+^ lymphomaA study of oral lorlatinib in patients with relapsed ALK^+^ lymphoma (CRU3)2Recruiting--NCT03505554--NA: ORR or CR are not available on the clinicaltrials.gov or from the published article although the trial has been completed*R-CHOP* rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone, *G-CHOP* obinutuzumab, cyclophosphamide, doxorubicin, vincristine and prednisone, *DA-R-EPOCH* rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin

BCL-2 {#Sec49}
-----

The BCL-2 family of proteins regulates the intrinsic pathway of mitochondrial apoptosis^[@CR457]^ and can be divided into three groups: anti-apoptotic proteins (BH1-4 domains), multi-BH domain pro-apoptotic proteins (BH1-3 domains), and BH3-only pro-apoptotic proteins. The t(14;18)(q32;q21) translocation is a common type of *BCL-2* translocation.^[@CR458]^ Mutated *BCL-2* affects cells in several aspects, such as proliferation, apoptosis, angiogenesis, and metastasis, resulting in the development of hematological malignancies.^[@CR459],[@CR460]^ *BCL-2* translocation is the major hallmark of FL (\>80% of samples); it occurs in bone marrow pre-B cells and leads to high BCL-2 protein expression.^[@CR461]^ Chromosome 18q21 amplification leads to BCL-2 overexpression and is observed in patients with MCL.^[@CR462]^ BCL-2 overexpression is also detected in approximately 30% of DLBCL.^[@CR463]^ The term double-hit lymphoma (DHL) refers to a subset of DLBCLs that present concurrent rearrangements of *MYC* and *BCL-2* (sometimes *BCL-6*).^[@CR464]^ DHL is present in 5--10% of DLBCL and is mostly classified as the GCB subtype, with highly aggressive clinical behavior and poor response to frontline regimens.^[@CR465],[@CR466]^ The term double-expressor lymphoma (DEL) refers to a subset of DLBCLs that show the coexpression of MYC (\>40%) and BCL2 (\>50%) by immunohistochemistry in the absence of chromosomal translocations. DEL is present in 25--30% of DLBCL and is mostly classified as the ABC subtype, which is also associated with poor clinical outcomes.^[@CR466],[@CR467]^

ABT-737, which binds to BCL-2, BCL-XL, and BCL-w with high affinity, had promising preclinical effects in CLL.^[@CR468],[@CR469]^ Navitoclax (ABT-263), the orally available derivative of ABT-737,^[@CR470]^ was shown to provoke transient thrombocytopenia in phase 2 trials of patients with B-NHLs due to the importance of BCL-XL for the survival of platelets.^[@CR471]^ A phase 1 trial of navitoclax combined with rituximab (NCT00788684) in lymphoid cancers is ongoing. Venetoclax (ABT-199), a highly selective BH3 mimetic, is designed to treat lymphomas with *BCL-2* translocations. A phase 1 trial (NCT01328626) of venetoclax in relapsed or refractory NHLs showed an ORR of 75% (CR 21%) in MCL, an ORR of 38% (CR 14%) in FL, an ORR of 18% (CR 12%) in DLBCL and an ORR of 67% (CR 0%) in MCL.^[@CR472]^ A phase 2 study (NCT02187861) of venetoclax plus rituximab vs. venetoclax plus BR in patients with relapsed or refractory FL was completed. The results showed an ORR of 32.7% (CR 13.2%) in the venetoclax plus rituximab group, an ORR of 45.1% (CR 27.5%) in the venetoclax plus BR group, and an ORR of 51% (CR 23.5%) in the BR group. Many clinical trials on combination therapy of venetoclax and chemotherapy or other targeted agents are active. In MCL, a phase 3 randomized, double-blind study (NCT03112174) to compare the efficacy and safety of the combination of ibrutinib and venetoclax vs. ibrutinib and placebo is ongoing. A phase 1 study (NCT03255096) on the combination of RO6870810 (a bromodomain inhibitor) and venetoclax, with or without rituximab, in relapsed or refractory DLBCL and high-grade B-cell lymphoma is ongoing. To test the effect of venetoclax in combination with chemotherapy, a study (NCT02055820) of venetoclax in combination with R-CHOP or obinutuzumab plus CHOP (G-CHOP) in previously untreated DLBCL was performed, and the results demonstrated an ORR of 87.5% (CR 79.2%) in the venetoclax plus R-CHOP group and an ORR of 87.5% (CR 78.1%) in the venetoclax plus G-CHOP group. Moreover, 87.5% of DEL patients achieved CR.^[@CR473]^ Another phase 1 trial (NCT03036904) of venetoclax plus DA-R-EPOCH is also active for aggressive B-NHLs.

BCL-6 {#Sec50}
-----

*BCL-6* was initially discovered as an oncogene in B-NHLs. The BCL6 protein is an evolutionarily conserved zinc finger transcription factor with an N-terminal broad-complex, tram track and bric-a-brac/Pox virus and zinc finger (BTB/POZ) domain and functions as a transcriptional repressor.^[@CR474]^ Transcription factors, transcriptional corepressors, signaling mediators, and catalytic enzymes can be regulated by BCL-6. Studies have shown that BCL-6 overexpression inhibits reactive oxygen species (ROS) generation and represses the apoptosis induced by chemotherapy in B-NHL cells.^[@CR475],[@CR476]^ Similar to BCL-2, BCL-6 is the key factor for the development and maintenance of GCs within lymphoid follicles. Once GC B-cells begin their differentiation into memory B-cells and PCs with an appropriate affinity for the inciting antigen, BCL-6 will be phosphorylated and subsequently degraded by the proteasome.^[@CR476]^ Moreover, BCL-6 regulates T~FH~ cell differentiation.^[@CR477],[@CR478]^ *BCL-6* translocations are found in 40% of DLBCL, 48% of nodular lymphocyte-predominant Hodgkin lymphoma, and 5-10% of FL.^[@CR445],[@CR479],[@CR480]^ ABC-DLBCL patients have more *BCL6* translocations than GCB-DLBCL patients (24% vs. 10%). In T-NHLs, BCL-6 is detectable in some types of PTCL, especially ALK^+^ ALCL and lymphomas derived from T~FH~ cells, particularly AITL.^[@CR481],[@CR482]^ Oncogene addiction is switched to *BCL-2* and *BCL-XL* in the context of BCL-6 inhibition.^[@CR483]^ To solve this problem, a combined treatment of RI-BPI (a BCL-6 inhibitor) and ABT-737 might be a choice but needs more experimental verification.

p53 {#Sec51}
---

The p53 transcription factor plays an important role in regulating cell survival by activating gene transcription that is involved in apoptosis and other biological functions.^[@CR484]^ Notably, p53 can interact with the BCL-2 pathway by directly and indirectly regulating the anti-apoptotic activity of the BCL-2 family of proteins.^[@CR485]^ With a negative feedback response, the E3 ubiquitin ligase MDM2 can bind p53 for degradation, maintaining a low expression level of p53 under normal conditions.^[@CR486]^ The dysregulation of p53 can be found in many types of lymphomas, including DLBCL (16--30%), MCL (21--45%), FL (9--29%), and MZL (8--12%).^[@CR458]^ It is often regarded as an independent prognostic factor for poor outcomes and a signal for chemotherapy resistance.^[@CR487]^ Targeting p53 can potentially restart apoptosis and trigger cell death. Idasanutlin (RG7388), a potent and selective MDM2 antagonist, when combined with obinutuzumab and venetoclax, showed significant antitumor activity in xenograft models.^[@CR488]^ A phase 1/2 trial (NCT03135262) of idasanutlin in combination with rituximab and venetoclax in relapsed or refractory DLBCL patients is ongoing. Selinexor, an inhibitor of exportin 1 (XPO1), inhibits the nuclear export of p53 and restores p53 nuclear localization. A phase 1 study (NCT01607892) of selinexor showed an ORR of 31% (CR 6%) in advanced NHLs.^[@CR489]^ A study of selinexor combined with chemotherapy (NCT03147885) in advanced B-NHLs is ongoing.

ALK {#Sec52}
---

ALK^+^ ALCL is characterized by the expression of ALK fusion proteins.^[@CR464]^ The major type of *ALK* fusion is the t(2;5)(p23;q35) translocation, which is detectable in approximately 75--85% of ALK^+^ ALCL.^[@CR490],[@CR491]^ All fusion proteins can activate the downstream oncogenic transcription factor STAT3 and promote proliferation and growth in cancer cells.^[@CR492]^ Many inhibitors are clinically available for targeting ALK tyrosine kinase activity, including crizotinib as a first-generation agent, ceritinib and brigatinib as second-generation agents and lorlatinib as a third-generation agent.^[@CR493]^ The study of crizotinib in relapsed and refractory ALK^+^ lymphomas showed an ORR of 90.5%, with a 2-year PFS of 63.7% and a 2-year OS of 72.7%.^[@CR494]^ Thus, a phase 2 trial of crizotinib (NCT02419287) and brigatinib (NCT03719898) in relapsed ALK^+^ lymphomas is ongoing. Moreover, because of acquired resistance from first- and second-generation agents, a phase 2 study (NCT03505554) to define the ORR of lorlatinib in patients with ALK^+^ lymphomas resistant or refractory to ALK inhibitors is ongoing.

Conclusions {#Sec53}
===========

With the understanding of the biological function of surface markers, signaling transduction pathways, and epigenetic modulations as well as the orchestration of the microenvironment with lymphoma cells in lymphoma progression, many novel agents and immune therapeutic strategies have been developed. These therapies enable clinicians to perform precision medicine and significantly improve the prognosis of patients. However, many questions remain to be answered, such as treatment scheduling, optimized dosage and combinations with other agents. The identification of potential biomarkers that can predict the clinical responses and toxicities of these targeted therapies is challenging. In conclusion, mechanism-based targeted therapy is a promising strategy to eventually make lymphoma a curable disease.
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